Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies.

Introduction to tumor cell plasticity (TCP)

Cellular plasticity is a fundamental feature of cells. During development, cells progressively differentiate into different hierarchies and obtain specific developmental commitments. Such processes are reversible, and the phenotypic changes can be diversely directed as needed. Genetic lineage tracing has demonstrated that functionally mature cells can undergo dedifferentiation (lineage reversion), transdifferentiation (cells converting into other distant lineages), or transdetermination (cells switching lineage commitment to a closely related cell type) upon injury or disease. 1 , 2 As far back as 1956, Conrad Waddington stated that during development embryonic progenitor cells progressively differentiate into distinct cell types and are increasingly restricted within a specific lineage. 3 The final specialized cells are then integrated into their respective tissues and conduct their specific invariable functions. However, later studies subverted this paradigm. Han Driesch isolated from a sea urchin embryo a single blastomere in an early multicellular state could develop into an entire larva. 4 This finding suggested that partially developed cells are not fully determined but retain the potency to produce all types of cells found in an entire organism.

In fact, the states of cells are quite dynamic, especially when injury or disease occurs. An equilibrium between new cell generation and old cell loss is generally maintained in multicellular organisms. If perturbed by unexpected loss, stem cell replication and differentiation along with transformation of mature differentiated cells can restore equilibrium. For example, endothelial cells assume arterial, venous, or lymphatic identity in an early developmental stage. However, upon injury, endothelial cells can undergo lineage changes to become hematopoietic progenitor or cardiac valve cells. 5 – 7 In liver homeostasis, the modest proliferation of hepatocytes in all zones contributes to the homeostatic hepatocyte pool, rather than a rare type of liver progenitor cell (LPC) subpopulation. 8 , 9 In a genetic mouse model which mimics human Alagille syndrome and contributes to biliary epithelium regeneration, hepatocytes are able to transdifferentiate into biliary epithelial cells. 10 Additionally, cellular plasticity can be “artificially” enhanced, as demonstrated by induced pluripotent stem cells (iPSCs), which were first generated in 2007, 11 providing unprecedented opportunities for novel therapies.

Cellular plasticity also contributes to pathological conditions. Similar to the cell plasticity observed during post-injury repair and regeneration, plasticity in tumor cells promotes survival against the immune attack and anti-tumor treatments. A major obstacle preventing complete remission, this evasion to therapy occurs as cancer cells play “hide and seek” by constant phenotypic switching. Some regard this phenotypic switching of cancer cells to result from passive Darwinian selection and enrichment upon drug exposure, 12 , 13 while others argue it is an active adaptation to internal or external stimuli (Lamarckian induction). 14 A coexisting model has also been formulated to illustrate that these two concepts complement and intertwine with each other (Fig. 1 ). 14 – 16 The “hide and seek” behavior of cancer cells is known as TCP, which is a process that re-activates various developmental programs to achieve phenotypic switching. TCP enables transformation of tumor cell identity that allows the cells to adapt to different microenvironments and circumvent the drug-targeted pathway. This subpopulation of tumor cells is characterized by its dormant and stem-like trait and termed drug-tolerant persisters (DTPs). 15 The “acquired inertia” of DTPs is regarded as a survival skill exposed by antitumor treatment that can fade away after a drug-free interval. 17 Thus, with TCP, a reversible switching of phenotypes can be achieved between proliferative, metastatic tumor cells and dormant, drug-indifferent DTPs, thereby hindering the desired outcome of targeted therapies. By this universally plastic behavior, tumor cells transform in different but functionally overlapping processes, including epithelial-mesenchymal transition (EMT), transdifferentiation, and acquiring properties of cancer stem cells (CSCs). 14 , 18 , 19 Fig. 1 Changes in acquired therapy resistance induced by treatment initiation and discontinuation, with different scenarios employed to interpret the development of the therapy-resistant phenotype. According to the Darwinian selection model, drug-tolerant persistors (DTPs) that originated from the primary tumor tissue are selected and enriched by treatments. The Lamarckian induction model regards the acquired drug-indifferent phenotype as the result of tumor cell adaptation to treatments that leads to formation of induced DTPs. The coexisting model suggests that formation of both primary and induced DTPs occur and together contribute to the acquired therapy resistance

Epithelial–mesenchymal transition

EMT is a process by which tumor cells lose their epithelial features and acquire mesenchymal characteristics. EMT is characterized by loss of apical-basal polarity and disruption of intercellular interactions, accompanied by the acquisition of front-rear polarity and remodeling of the cytoskeleton. 20 , 21 On the other hand, mesenchymal-epithelial transition (MET) is the inverse process of EMT. EMT and MET are thought to be regulated mainly at the transcriptional level by the activity of EMT transcription factors (EMT-TFs), including Snail, Slug, Zeb1/2, Twist, and microRNAs (miRs). Signaling pathways such as transforming growth factor (TGF-β), wingless/integrated (WNT), NOTCH, and HIPPO are also involved. 15 , 22 Two double-negative feedback loops that include Snail/miR-34 and Zeb/miR-200 help to manipulate the initiation, transition, and maintenance of EMT program. 23 , 24 Genetic mutations may also play a role in EMT regulation. As indicated by Martin et al., 25 a combined loss of the tumor suppressor gene P53 and PTEN in clonal prostate epithelial cells can lead to transformation of multipotent progenitors and ultimately EMT. Yamasaki et al. 26 recently proposed that Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutation can also promote an EMT-like phenotypic change.

Both EMT and MET have been proposed to play key roles in cancer progression. 21 Apart from a complete EMT/MET transition, tumor cells can exhibit a “partial EMT” state, a hybrid of epithelial and mesenchymal phenotypes. 27 In fact, tumor cells can exhibit a spectrum of EMT states characterized by varying proportions of epithelial and mesenchymal traits, both in circulation and at a secondary site. 28 , 29 Panchy et al. 30 recently confirmed this epithelial-mesenchymal spectrum using transcriptomic analysis. This hybrid epithelial-mesenchymal state enables tumor cells to self-adapt and adjust quickly to changing environments, thus representing an ideal mechanism of TCP. 28 Previous studies indicate that dynamic changes between epithelial and mesenchymal phenotype in tumor cells with partial EMT are critically important to the metastatic potential and therapy resistance of tumor cells. 31

The contributions made by EMT programs to metastasis were first proposed by Yang et al., 32 who described that inhibition of Twist, a classic EMT-TF, can significantly restrain highly metastatic mammary carcinoma cells from metastasizing to the lung. The impact of other EMT-TFs on metastasis was then extensively investigated in different types of cancers. 33 For example, depletion of Zeb1 was found to markedly inhibit pancreatic ductal adenocarcinoma progression towards metastatic type. 34 Zeb1 was also found to function as a key master regulator of multiple EMT-TFs and metastasis in breast cancer. 33 The MET program, in contrast, presumably functions during metastasis when the migratory CSCs settle down and adapt to a new microenvironment. In the process of colonization, the migratory CSCs regain self-renewal capacity and spawn fast-cycling epithelial progeny, thereby restoring epithelial characteristics. 35 Such reversible EMT-MET programs seem to be a common feature shared by different cancer types during the seeding of a secondary tumor. 35 – 37

Evidence also suggests that EMT can serve as a survival mechanism for cancer cells to escape immunosurveillance and resist therapy-induced death. 38 Multiple studies have observed a strong correlation between the level of mesenchymal cell markers and therapeutic resistance. 21 , 39 – 42 For example, Farmer et al. 42 demonstrated that an upregulation of stromal gene expression predicted resistance to preoperative chemotherapy with 5-fluororacil, epirubicin, and cyclophosphamide in estrogen receptor (ER)-negative breast cancer. In ovarian cancer, inhibition of EMT can effectively eliminate cisplatin resistance. 43 Byers et al. 40 revealed a correlation between a 76-gene mesenchymal signature and non-small-cell lung cancer (NSCLC) resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) inhibitors. By proteomic screening, Paulitschke et al. 41 also found that two EMT-related markers are effective in determining drug susceptibility in melanoma cells. Although the mechanisms underlying the therapeutic resistance conferred by EMT remain unclear, several hypotheses have been put forward, including reduced levels of proapoptotic proteins, increased drug efflux, and immunosuppressive tumor microenvironment (TME). 44 – 46

Transdifferentiation

Transdifferentiation, also known as lineage plasticity or lineage switching, is a radical shift in cell identity that leads to cells acquiring new transcriptional or morphological characteristics. 47 , 48 In the context of cancer, such lineage plasticity may serve as a promising therapeutic approach. For example, melanoma spheroid cells are able to transdifferentiate into benign cell lineages including melanocytes, adipocytes, osteocytes and chondrocytes. 49 However, transdifferentiation in cancer cells can also be a double-edge sword. Transdifferentiation observed in basal cell carcinoma (BCC) contributes to BCC relapse following treatment discontinuation. 50 , 51 When treated with vismodegib, some BCC cells transitioned from a phenotype featuring a transcriptional bulge-like signature to a mixed isthmus/interfollicular epidermis cell phenotype, thereby achieving drug resistance. 52 A discontinuation of treatment led to tumor cell reactivation and resumption of proliferation. 52 , 53 Another distinctive form of transdifferentiation is characterized by a drug-induced neuroendocrine transdifferentiation (NET). Observed in prostate cancer (PC) and lung adenocarcinoma (LUAD), NET induces drug resistance, thereby causing treatment failure and relapse. 14 , 54 , 55 Here, we consider PC and LUAD as two typical examples of NET for further discussion.

Through NET, PC tumor cells gradually obtain the histomorphology of small cell prostate cancers (SCPC) that are “therapy indifferent” to androgen receptor signaling inhibitors (ARSi). 54 , 56 The switch from PC to SCPC is characterized by the presence of neuroendocrine markers (chromogranin A, synaptophysin, and others), and the absence of androgen receptor (AR) and serum prostate-specific antigen. 57 Functionally, SCPC cells have an elevated metastatic potential, enhanced stemness, heightened therapeutic resistance, and a worse prognosis. 18 , 58 Inactivation of TP53 , RB1 , PTEN , and amplification of MYCN have been reported to be involved at the molecular level of the cell identity shift. 18 , 59 Mutations in these candidate genes provide a specific genomic background that enables epigenetic regulation towards tumor plasticity. 48 , 60

Moreover, epigenetic events are also indispensable. NET of PC cells towards SCPC is associated with the well-established undifferentiated cell marker SRY-Box Transcription Factor 2 (SOX2), epigenetic regulator histone methyltransferase enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2), and RE1-silencing transcription factor (REST). 14 , 18 , 61 – 64 A recent study by Cyrta et al. 65 suggested that the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complexes may also be a potential regulator of SCPC lineage plasticity. Correspondingly, SCPC can be reverted to its original lineage by the re-establishment of TP53 and RB1 as well as re-exposure to androgens, or inhibition of SOX2, thus re-sensitized to ARSi treatment. 61 , 62 This reversibility of lineage plasticity could be of critical importance as a future target in PC therapy.

Like SCPC, LUAD undergoes NET through LUAD – small-cell lung cancer (SCLC) transition, which enables the tumor to escape from EGFR-TKI treatment and gain a higher level of malignancy. 48 , 54 , 66 Although NET is also identified in non-EGFR-mutant NSCLC, EGFR mutant LUADs are more likely to switch lineage. 67 Oser et al. 68 reported that 5–15% of EGFR mutant LUAD patients with TKI resistance showed small cell histology in relapsed tumors, and became sensitive to SCLC chemotherapy. 48 The mechanism of LUAD NET at the molecular level is similar to that of PC NET. LUADs with loss of TP53 and RB1 expression are more likely to transdifferentiate into SCLC tumors, which suggests that these two genes may be critical in promoting transdifferentiation towards a neuroendocrine identity. 60 , 68 – 70 The epigenetic regulator EZH2 is also regarded as a potential therapeutic target to reverse NET. 71 , 72

PC and LUAD are currently the most extensively studied cancers exhibiting NET; however, transdifferentiation of epithelial cells is more common. According to a recent study, many epithelial cancers, including bladder, endometrial, and gastric cancer with neuroendocrine gene expression signatures tend to exhibit high-grade tumors and poor prognosis. 66 This finding indicates that a latent neuroendocrine lineage plasticity may occur in multiple tissues.

Cancer stem cells

Accumulating evidence suggests that the existence of CSCs within tumor tissues is responsible for tumor initiation and intertumoral heterogeneity. CSCs have the potential to proliferate infinitely, self-renew, and differentiate. 73 , 74 A recent study proposed that a CSC is a highly plastic state that results in fast adaptation of tumor cells to varying conditions in the TME. 75 Previous studies revealed CSCs and adult stem cells share multiple signatures, including the surface markers CD133, CD44, CD24, CD26, CD166, and EPCAM, and intracellular proteins like ALDH1. 76 – 78 Additionally, CSCs and stem cells also share similar developmental related signaling pathways, such as WNT, NOTCH, and Hedgehog (Hh). 29 , 79

Like normal stem cells, CSCs propagate through asymmetric division, which produces one daughter cell that remains a CSC and one committed progenitor cell that differentiates into a non-CSC. 80 , 81 Symmetric division can also occur simultaneously, with the production of either two CSCs (symmetric renewal) or two committed cells (symmetric commitment). 80 , 82 The transition between CSC and non-CSC states seems irreversible and dynamically balanced. Under certain circumstances, however, the balance can shift in either direction. A shift towards renewal results in replenishment of the CSC pool and consequently produces a more aggressive, undifferentiated phenotype. A shift towards non-CSCs suggests tumor-formation. 29 Equilibrium represents the plasticity of tumor cell fate and can be manipulated by various influencing factors. For example, a second mutation introduced in chronic-phase chronic myeloid leukemia (CML) has been found to trigger an imbalance that favors symmetric renewal and results in higher malignancy. 83 EMT-TF Twist2 has been reported to induce stemness properties in lung CSCs by moving the balance towards symmetric division, while repressing asymmetric division. 84 Other epigenetic regulations, including deoxyribonucleic acid (DNA) methylation, histone modification, and bivalent chromatin state, have been found to contribute to CSC plasticity. 78 , 85 These studies indicate that manipulation of CSC division may be promising for cancer control.

CSCs and EMT share a high degree of consistency and may be a partially overlapping concept. 86 , 87 As mentioned, the EMT program largely facilitates tumor cell dissemination. CSCs are also enriched in disseminated tumor cells and feature EMT expression signatures. 88 Circulating tumor cells express a remarkably congruent transcriptomic profile with CSCs and have been found to overexpress both EMT and stem cell markers. 89 CSCs led to therapeutic resistance through various mechanisms. For example, CSCs can specifically inherit effective drug-discharging ATP-binding cassette (ABC) transporters from asymmetrical division, which enable tumors to sustain long-term expansion. 90 , 91 CSCs can also facilitate efficient DNA damage. 92 – 94 Another mechanism of therapeutic resistance in CSCs is the formation of a protective niche, an immunosuppressive microenvironment characterized by low infiltration of immune cells and downregulated signaling by the programmed cell death ligand 1(PD-L1). 79 , 95 Non-CSCs also help to maintain of a pool of CSCs by secreting supportive signals such as WNT and brain-derived neurotrophic factor (BDNF), as well as supportive factors such as interleukin (IL)-6 and IL-8. 96 – 98

Mechanism of therapy-induced TCP

Various therapies have been developed to prolong survival and improve the quality of life of cancer patients, yet therapy-induced drug resistance remains a major challenge to achieving the desired clinical outcomes. Notably, up to 90% cancer-associated deaths are attributed to drug resistance. 99 Acquired drug resistance can be induced by targeted treatments and is associated with TCP, the “hide-and-seek” behavior of cancer cells. The drug-resistant phenotype of cancer cells is not heritable but is a transient and reversible process. 16 Therefore, a comprehensive understanding of the mechanism of such induced plasticity should greatly facilitate the development of novel therapies. Epigenetic alterations, transcription factors, key signaling pathways, and TME can each potentially contribute to the therapy-induced plasticity in multiple cancers.

Epigenetic mechanisms

Therapy-induced epigenetic plasticity largely contributes to the reprogramming of tumor cells and phenotypic switching towards therapy resistance. The epigenetic modifications can be either chemical (DNA methylation and histone modification) or structural (chromatin remodeling and inter/intrachromosomal interactions) 100 , 101 (Figs. 2 a and 3 ). Fig. 2 Therapeutic resistance involvement in epigenetic modifications and EMT/MET. a Schematic representation of therapy-induced drug resistance through chemical epigenetic modifications. Four core histone proteins (H2A, H2B, H3, and H4) can be diversely modified by multiple enzymes that result in methylation, acetylation, phosphorylation, or ubiquitylation. DNA can be methylated at the 5-carbon of the cytosine base to form 5-methylcytosine (5-mC), which can be further oxidized to form 5-hydroxymethyl cytosine (5-hmC). Enzymes involved in the epigenetic modifications of either histone or DNA can be utilized as potential future therapeutic targets against tumor cell plasticity. K, Lysine; S, Serine; R, Arginine; T, Threonine; me, methylation; ac, acetylation; ub, ubiquitination; P, phosphorylation; HAT, histone acetyltransferase; HMT, histone methyltransferase; HDAC, histone deacetylase; HDM, histone demethylase; TRIM, tripartite mortif; MSK1, mitogen- and stress-activated protein kinase 1; DNMT, DNA methyltransferase; TET, ten-eleven translocation enzymes. b Primary tumor cells undergo EMT and MET to achieve metastasis. Primary tumor cells undergo EMT by losing epithelial traits and acquiring mesenchymal characteristics, which enables tumor cells to migrate and invade into blood or lymphatic vessels. In circulation, tumor cells exhibit a “partial EMT” within the epithelial-mesenchymal spectrum. During colonization, migratory tumor cells with mesenchymal traits undergo MET to restore epithelial characteristics and proliferate to form a secondary tumor. Therapeutic resistance and invasiveness are higher in mesenchymal states, whereas a hybrid state of epithelial and mesenchymal indicates the highest level of stemness and capacity of self-adaptation. The process of EMT/MET is regulated by crosstalk among genomic factors, MET-TFs, and multiple signaling pathways. EM, epithelial-mesenchymal transition, MET mesenchymal-epithelial transition, TF transcription factor, miR microRNA Fig. 3 Mechanisms driving tumor cell plasticity and drug resistance. Both tumor microenvironment factors and EMT-related signaling pathways regulate the EMT process. The activation of EMT facilitates the dedifferentiation of non-cancer stem cells (CSCs) to CSC, which contributies to tumor heterogeneity

DNA methylation is widespread in the human genome and functions differently based on various methylated regions. 99 The aberrant methylation status of gene promoters plays an instrumental role in acquired drug resistance in a variety of tumor types. 102 , 103 The most common mechanisms of drug resistance include hypomethylation of gene promoters of drug efflux, hypermethylation of promoters of pro-apoptotic genes, and altered methylation levels of DNA-repair genes. 99 Global loss of DNA methylation and histone acetylation has been observed in therapy-induced drug-resistant tumor cells under extended treatment with the neoadjuvant aromatase inhibitor (letrozole). Such epigenetic alterations result in tumor cells escaping from dormancy and acquiring resistance after targeted therapy in breast cancer patients. 104

In contrast, indifference or resistance to endocrine therapy in ER-positive breast cancer is due to hypermethylation of estrogen-responsive enhancers. 105 Moreover, effective therapies targeting the AR in PC inadvertently promote NET. The lineage switching into neuroendocrine PC was associated with increased DNA methylation, turning the original PC into a lethal, castration-resistant type. This process can be reversed by inhibition of DNA methyltransferase (DNMT). 106 Histone modification, represented by euchromatin histone lysine methyltransferase 2 (EHMT2), has been implicated in acquired drug resistance following targeted therapy. EHMT2 overexpression was observed in erlotinib resistance in NSCLC, leading to transcriptional activation of PTEN and repressed Akt signaling, whereas inhibition of EHMT2 reverses the acquired indifference to therapy and re-sensitizes NSCLC cells to EGFR-TKI treatment. 107 Histone modifications, either via EHMT2 or histone deacetylase 3 (HDAC3), can result in acquired resistance against mitogen-activated extracellular signal-regulated kinase inhibitors (MEKi) treatment in pancreatic ductal adenocarcinoma (PDAC). 108

Structural epigenetic alterations, including changes in high-order structures of chromatin and interactions among distal regulatory elements, may also be involved in therapy-induced TCP. For example, targeted therapy using γ-secretase inhibitors in T cell acute lymphoblastic leukemias (T-ALL) can induce the expansion of a rare group of pre-existing persister cells. These persisters contain more compact chromatin and higher levels of repressive histone modifications compared to γ-secretase inhibitor-sensitive naïve cells. 109 Similar to trametinib-resistant triple-negative breast cancer (TNBC), remodeling of enhancers and promoters was observed accompanied with adaptive transcriptomic responses. 110

The role of transcription factors in controlling TCP

A network of transcription factors also plays an important role in TCP against targeted therapy. EMT-TFs like Twist and Snail actively respond to targeted therapy during the EMT process and result in enhanced plasticity and mesenchymal switching. 111 , 112 In addition to multiple EMT-TFs, several other transcription factors function in controlling TCP.

AR is known as a ligand-activated transcription factor which regulates gene expression in the prostate epithelium. 113 AR-targeted inhibitors, including bicalutamide and enzalutamide, have been developed for PC treatment. 114 , 115 However, upon castration therapy, evading mechanisms are launched by AR amplification, point mutation, splicing variants, as well as substitution of AR functions by glucocorticoid receptors. 116

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that has been studied extensively in multiple cancers. Previous studies have suggested that STAT3 activation is associated with trastuzumab as well as trastuzumab-emtansine resistance in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 117 , 118 In triple-negative (ER-/PR-/HER2-) breast cancer (TNBC) patients, a strong transcriptomic response was observed after treatment with trametinib for seven continuous days, with up to 22% of the transcriptome either significantly up- or downregulated. 110 The super transcription factor cellular MYC underwent rapid degradation during the treatment process and functioned as a controller of genomic reorganization and transcriptional complex recruitment in the phenotypic change of tumors. 110 , 119

In melanoma, an assay for transposase-accessible chromatin using sequencing (ATAC-seq) revealed an initial loss of transcription factor binding sites, followed by an increase in accessible sites, during BRAF inhibition (BRAFi) treatment. These results indicated that targeted therapy altered transcription factors. 120 According to a recent study by Yang et al., 121 activating transcription factor 4 (ATF4) stress signaling led to rapid tumor evasion within a few days after the initiation of mitogen-activated protein kinase (MAPK) pathway inhibition, and was accompanied by elevated levels of microphthalmia-associated transcription factor (MITF). This was followed by tumor cell dedifferentiation and a dormant phenotype marked with decrease in MITF expression. Additionally, the helix-loop-helix transcription factor inhibitor of DNA binding 3 (ID3) was upregulated after BRAFi therapy compared to that in the pretreatment state. ID3 acted as a transcriptional repressor of sex-determining region Y-box 10 (SOX10) and MITF, thereby promoting tumor cell transformation to a drug-resistant phenotype. 122 Moreover, Sun et al. 123 also observed an increase in the percentage of SOX10 low EGFR high melanoma cells after BRAFi and MEKi treatment. This subset of tumor cells displayed a slow-cycling phenotype in response to these targeted drugs, highlighting the potential of transcription factors to mediate plasticity in melanoma.

The regulation patterns of the numerous known transcription factors are quite distinct in targeted therapy-induced tumor cell lines. 120 , 124 This complexity indicates that tumors acquire resistance against targeted therapies in a patient- and drug-dependent manner. Hence, the transcription factors and their interaction modes remain to be explored.

Key signaling pathways in controlling TCP

Numerous signaling pathways are involved in embryonic development, and a re-activation of these signaling pathways is critical in tumor progression and therapy resistance. Interaction of these conserved signaling pathways (e.g., Hh, Wnt, and Notch pathways) and their crosstalk with other oncogenic pathways (e.g., Nuclear factor kappa B (NF-κB), PI3K/AKT/Mammalian target of rapamycin (mTOR), and MAPK pathways) contributes significantly to TCP by regulating the fluctuating expression of downstream effectors 125 – 128 (Fig. 2b ). Phenotypic switching driven by multiple signaling pathways is a huge challenge to successful tumor treatment.

Alterations of the Hh (Hedgehog) signaling pathway occur in one-third of cancers, and deregulation of the Hh signaling pathway plays an important role in therapeutic resistance. 15 , 129 – 132 Aberrant activation of Hh signaling and subsequent upregulation of downstream effector glioma-associated transcription factor 2 (GLI2) was observed in bortezomib-resistant myeloma cells. 133 , 134 Further studies demonstrated that Hh signaling is involved in CSC self-renewal in multiple myeloma, and blocking Hh signaling can lead to CSC differentiation. 135 In TNBC, the Hh ligand produced by tumor cells can reprogram cancer-associated fibroblasts (CAFs) to promote a CSC-phenotype switching and the acquisition of chemo-resistant traits. 136 Therefore, an effective Hh signaling pathway blockade is capable of lowering CSC proliferation, metastasis, and the EMT program, thereby controlling TCP.

Wnt signaling pathway is also highly associated with TCP. Wnt signaling is complex and can function through either an autocrine or a paracrine mode, by canonical (Wnt/β-catenin pathway) or non-canonical (the planar cell polarity pathway) pathways. Wnt signaling contributes to EMT regulation and TCP. 137 In most cases, the Wnt/β-catenin signaling pathway is constitutively activated, which increases the expression of Snail, a regulator of EMT. Inhibition of the Wnt/β-catenin pathway inhibits EMT and tumor metastasis in a colorectal cancer model. 138 Slug is another EMT modulator that is considered to be a downstream protein in Wnt/β-catenin-mediated tumor invasion. Moon et al. reported that concurrent expression of β-catenin and Slug predicts lymph node metastasis and survival rate in patients with head and neck squamous cell carcinoma. 139 Overexpression of Slug can induce cancer cell stemness and enhance cell invasion and metastasis. Sun et al. reported that Slug overexpression is associated with the invasiveness of liver cancer both in vitro and in vivo. 140 In contrast, overexpression of Snail did not have a similar effect in liver cancer cells. The Wnt pathway has been linked to increased expression of another EMT transcription factor, Twist, in mammary epithelial cells. 141 , 142

Accumulating data show that TWIST not only induces EMT, but also promotes the formation of CSCs and enhances tumorigenesis. 143 Therefore, inhibiting these EMT mediators may represent the strategy for inhibiting tumor metastasis and recurrence. Additionally, activation of the Wnt signaling pathway reportedly controls the stemness of CSCs in different types of cancers including hepatocellular carcinoma (HCC), and colon, lung, and other cancers. 144 – 148 According to clinical practice, targeted treatment using MEKi (selumetinib, trametinib, and PD318088 ) inadvertently increased Wnt activity and led to enhanced stemness and tumor relapse in colorectal cancer. 149 Similarly, valproic acid, which was originally regarded as a histone deacetylase (HDAC) inhibitor in breast cancer treatment, can activate Wnt signaling pathway and promote the pool of mammary CSCs, leading to tumor progression. 150 Hence, attention should be paid to unexpected phenotypic switching regulated by Wnt signaling pathway in the processes of targeted therapy.

The Notch signaling pathway also enriches CSCs and regulates the EMT program in multiple cancers, including breast and lung cancer, pancreatic ductal adenocarcinoma, and malignant mesothelioma. 151 – 155 A previous finding showed a change in EMT status in lung adenocarcinoma upon treatment with gefitinib. 156 Subsequent studies further confirmed that the EMT process resulted from the activation of Notch-1 signaling pathway and led to gefitinib-acquired resistance. 157 Notch signaling is one of the master regulators of neuroendocrine transdifferentiation in NSCLC, which enables NSCLC to transdifferentiate into SCLC and acquire resistance to EGFR-TKIs after initial targeted treatment. 154

By extension, the Notch pathway has been discovered to play a crucial role in the EMT process in prostate cancer cells, promote a transformation towards basal stem-like properties, and lead to a castration-resistant phenotype. 158 , 159 Components of the Notch signaling pathway are expressed at significant levels in tumor invasive regions, which suggests its crucial role in EMT regulation. A recent paper by Natsuizaka et al. reported that Notch1 signaling and EMT work closely to promote squamous cell carcinoma tumor initiation. Moreover, another important protein, TGF-β, guides Notch1 to drive EMT. 160 A study by Zeng et al. showed that inhibition of Notch1 reverses the EMT process and overcomes cisplatin resistance in breast cancer cells. 161 The data also suggested that high expression of Notch1 predicts a poor prognosis in TNBC patients. Saad et al. demonstrated that the Notch-mediated activation of EMT is associated with the regulation of EMT transcription factors. 162 The two transcription factors, Snail and Slug, are involved in the inhibition of E-cadherin and β-catenin mediated by the Notch pathway. Inhibition of Notch activation limits the increase of MMP-2 and −9 expression, while it decreases Snail expression. The study provided direct evidence that Notch signaling induces EMT via the Snail pathway. Surprisingly, Notch signaling can synergistically work with other pathways to facilitate the EMT process. The crosstalk between these pathways is mediated by suppressor of mothers against decapentaplegic (SMADs) proteins that associate with other transcription factors for regulating the expression of genes required for the transition to mesenchymal characteristics. A single-cell sequencing study by Deshmukh et al. revealed both sequential and parallel activation of EMT signaling pathways. The Notch pathway also functions as a crucial regulator of TGF-β–induced EMT. 163

The role of TME in controlling TCP

TME is a key player in TCP induced by targeted treatment. The characteristics of TME, including immune and stromal cells, cytokines, exosomes, hypoxia, pH change, nutritional deficiency, and angiogenesis, are key regulators of TCP. 164 – 167

CAFs are recognized as major contributors in the crosstalk between tumor cells and adjacent stromal cells. 168 By producing a variety of bioactive molecules such as growth factors and cytokines, CAFs exert a profound impact on TME and influence TCP, 96 , 169 , 170 and have long been described as crucial players in the EMT program. CAFs also participate in CSC pool expansion. 171 – 173 The effect of CAFs in manipulating therapy resistance was reported by Apicella et al. 174 In this study, a prolonged treatment with TKIs generated resistance to erlotinib in vivo, but not in vitro. This intriguing phenomenon was explained by the existence of CAFs. Erlotinib treatment in vivo induces a metabolic rewiring towards aerobic glycolysis and increases lactate production; the secreted lactate triggers the overproduction of hepatocyte growth factor (HGF) in CAFs. Engulfed lactate and the subsequently increased HGF then activate the MET signaling pathway in cancer cells and cause resistance to erlotinib. 175 – 177 Moreover, hypoxia-induced glycolysis represses natural killer (NK) cells via lactate accumulation and reduces cytotoxicity by decreased level of NKG2D, CD16, perforin, and granzyme B, thereby forming an immunosuppressive TME. Such hypoxia-related TME conditions were reported to play a role in resistance to therapeutic monoclonal antibodies. 178 , 179

Cytokines secreted by immune and stromal cells also provide clues for acquired TCP induced by targeted therapy. 180 – 182 According to Li et al., 183 IL-6 in EFGR-mutant NSCLC patients was significantly increased upon osimertinib therapy. This associated Upregulation of laminin α5, which is among the most widely distributed laminins and is a major component of extracellular matrix (ECM), also occurred. By upregulation of laminin α5, IL-6 remodeled ECM and activated a downstream target focal adhesion kinase (FAK), thus contributing to acquired resistance against Osimertinib. 183 – 185 FAK activation was confirmed to be dispensable for IL-6 production in the maintenance of mesenchymal stem cells and can lead to acquired resistance of gefitinib as well. 186 , 187

Contribution of TCP to targeted therapy resistance

Targeted therapy is one of the most successful treatments that strike at the heart of a wide range of cancers. Nonetheless, the emergence of drug resistance significantly impairs the efficacy of targeted drugs and contributes to cancer mortality. Drug target mutations and activation of bypass pathways are known to confer resistance in cancer cells to targeted inhibitors. With an increasing understanding of TCP, it is now recognized that TCP is an important factor in mediating drug resistance. In this section, we focus on the role of TCP in shaping tumor cell characteristics and mediating targeted therapy resistance (Fig. 4 ). Fig. 4 Therapeutic strategies targeting tumor cell plasticity. Three main strategies can be used in combination treatment against tumor cell plasticity: 1) prevent tumor cell plasticity; 2) reverse the phenotypic switching; and 3) direct therapy to target the induced therapy-resistant tumor cells

Epithelial–mesenchymal transition related factors in mediating drug resistance

As described above, EMT plays a critical role in mediating TCP and resistance to targeted therapy. The principal mechanisms of EMT-related drug resistance can be attributed to slow cell proliferation, increased drug efflux, and escape from apoptosis. Lung cancer is by far the most well-documented subtype of cancer that links EMT and targeted drug resistance. Namba et al. demonstrated that the upregulation of EMT-related gene AXL contributes to acquired resistance to osimertinib. 188 Other EMT-related transcription factors, such as Snail, Slug, and ZEB1/2, are also reported to cause TKI resistance by regulation of EMT-related signaling pathways. 189 – 191 Therefore, a comprehensive understanding of the EMT process is critical to combat targeted therapy resistance. In this subsection, we delineate the current research on signaling pathways and related factors that modulate EMT associated with drug resistance.

Signaling pathways including Notch, Wnt/β-catenin, and TGF-β play crucial roles in activating EMT-related transcription factors. 192 Evidence supports that EMT transcription factors are involved in targeted therapy resistance, especially towards EGFR inhibitors. Consequently, signaling pathways that regulate the EMT process are important in mediating drug resistance. Chang et al. reported that Slug contributes to gefitinib resistance in NSCLC cells through downregulation of Bim and inhibition of caspase-9 activity. 193 Among EMT inducers, TGF-β is significant because of its potency in inducing EMT and its roles in cancer-associated EMT. 194 TGF-β-induced EMT is essential in cellular activities such as glycolysis and lipid/choline metabolism reprogramming. 195 In response to TGF-β, cancer cells undergo complete or partial EMT, where epithelial and mesenchymal markers co-exist on cancer cells. 37 The partial EMT status is characterized by an aggressive phenotype that renders cancer cells with high stemness and cell plasticity. 196 Upon stimulation of TGF-β receptors, TGF-β signaling is divided into SMAD-dependent and -independent pathways. Both TGF-β/SMAD and non-SMAD pathways play a significant role in mediating EMT and promoting cell plasticity. 197 Additionally, signaling pathways such as PI3K/AKT, mTOR, and MAPK are reported to play essential roles in TGF-β-induced EMT. 198 , 199 Surprisingly, TGF-β-induced EMT can be reversed. A study conducted by Katsuno et al. found that upon TGF-β removal, mesenchymal cells revert to an epithelial cell phenotype. 200 Moreover, prolonged TGF-β exposure promotes a stable EMT process in cancer cells, which is accompanied by increased tumor stemness and cancer drug resistance. The authors also identified that mTOR inhibitors can be a promising agent to target CSCs by antagonizing the TGF-β-induced EMT process.

MicroRNA (miRNAs) are small non-coding RNAs that play a pivotal role in the regulation of both EMT that promotes tumor metastasis and MET that facilitates metastatic colonization. 201 EMT-related miRNAs are documented to impact cancer cell stemness and drug resistance. Recent evidence showed that miRNAs may affect the EMT process by targeting related transcription factors, including Snail, Slug, Twist, and ZEB1/2. 202 The expression level of the Snail transcription factor may be controlled by multiple metastasis-related miRNAs, including miR-153, miR-203, miR-204, and miR-34c. 203 The miR-30 family are well-documented mediators of EMT transcription factor Snail in different cancer subtypes, including lung and breast cancer. 204 Liu et al. showed that miR-1 and miR-200 can inhibit EMT and mesenchymal differentiation via Slug-dependent mechanisms. 205 Other newly identified EMT-related miRNAs include miR-27b-3p, 206 which promotes the generation of circulating tumor cells, and miRNA-490-3p, which promotes the metastasis of invasive ductal carcinoma. 207 Nonetheless, recent studies have reported that some miRNAs, such as miRNA-128 MiRNA-155-5p, 208 , 209 are able to hinder the EMT process through inhibition of diverse EMT-related signaling pathways. With the increased understanding of miRNAs in EMT and TCP, different strategies focused on hindering miRNA function or miRNA delivery into tumor cells can be utilized to overcome cancer drug resistance.

Tumor heterogeneity

Tumor heterogeneity is defined as the existence of a subpopulation of cancer cells with different genotypes and phenotypes that exhibit various characteristics within a primary tumor. Heterogeneity may lead to divergent sensitivity to treatment and facilitate the development of drug resistance. 210

The most recent tumor heterogeneity model is known as the CSC plasticity model. 211 CSC is a subpopulation of cancer cells with self-renewal capacity to switch between stem and differentiated states. This dynamic transition can be attributed to gene mutations, epigenetic modification, as well as changes in TME. It should be noted that the EMT signaling pathway plays a central role in mediating CSC transition, which promotes cancer metastasis, recurrence, and drug resistance. Morel et al. reported that the induction of EMT can enhance human breast epithelial cell stemness and tumorigenic characteristics, 212 which has also been confirmed in colorectal, pancreatic, and liver cancers. 213 – 215 Quintana et al. demonstrated that most of the phenotypic heterogeneity in melanoma can be explained by the phenotypic plasticity model. 216 Although they did not identify a marker that can significantly distinguish tumorigenic from non-tumorigenic cells, CD271 + cells were shown to have little tumorigenic activity. However, the results were inconsistent in different studies, 217 suggesting that the role of cell plasticity in tumor heterogeneity may vary in cancer subtypes. Another study carried out by Charles et al. showed that nitric oxide can enhance the tumorigenic capacity of platelet-derived growth factor (PDGF)-driven glioma cells in vivo; therefore, it reversibly promotes their ability to form tumors. 218 Nakano et al. reported the dynamic equilibrium between CSCs and non-CSCs in the development of colorectal cancer. Such equilibrium is mainly controlled by EMT-related TGF-β signaling pathway. 219 One study demonstrated that, in colon cancer cells, the ablation of LGR5 + CSCs allowed the cancer cells to dedifferentiate into CSCs, which highlights the distinct CSC dependency for primary and metastatic tumor growth. 220

Multiple studies showed that a high level of tumor heterogeneity is associated with poor response to targeted drugs, including osimertinib, rociletinib, and gefitinib. 221 – 223 Chabon et al. demonstrated that multi-drug resistance was observed in 46% patients after targeted therapies, suggesting a frequent intra-tumor heterogeneity. 222 TCP, i.e., phenotype switching between different signaling pathways, can potentially lead to heterogeneity under therapeutic selective pressure. As mentioned above, cell plasticity is essential in multiple crucial biological processes, including embryonic development, wound healing, and tissue regeneration. In tumors, the reactivation of these mechanisms allows tumor cells to switch between non-CSC and CSC-like phenotypes, leading to tumor progression, metastases, and drug resistance. 224 Easwaran et al. performed a genome-wide analysis and found that silencing abnormal DNA methylation of promoters can decrease changes of plasticity of cell population and help in locking cell clones with abnormal retention of self-renewal capacity. 225 Therefore, an effective approach to disrupt TCP may represent a promising strategy to tackle tumor heterogeneity and overcome drug resistance.

Interplay between TCP and TME

A tumor is not only a group of cancer cells, but also a complex interaction between cancer cells and their surrounding environment, known as the tumor microenvironment (TME), which has attracted substantial research and clinical interest in recent years. 226 TME consists of tumor, immune (macrophages and lymphocytes), and stromal (stromal fibroblasts and endothelial cells) cells, blood vessels, and extracellular matrix (ECM). 227 Accumulating data show that cancer cells are able to control the function of cellular and non-cellular components through complex signaling pathways. 228 The cell-cell and cell-ECM interactions force non-malignant cells to acquire new phenotypes that facilitate the formation, progression, and metastasis of tumor cells. In addition, theinteractions of cancer cells with their TME are crucial to stimulate tumor heterogeneity, clonal evolution, and mediate drug resistance. 229

TCP allows tumor cells to switch phenotypes and survive treatment through adaptive strategies, and the TME is involved in mediating TCP. 165 For example, both cancer-associated fibroblasts (CAFs) and hypoxia contribute to oxidative stress, which is an important mediator of multiple adaptive strategies. Hypoxia is a hallmark of the TME and strongly linked to malignant progression, poor clinical response, and therapy resistance. 230 Recent studies have shown that hypoxia may induce phenotypic switching, leading to drug resistance. Terry et al. reported that hypoxic stress induces phenotypic diversity of EMT in lung cancer, and leads to changes in EMT transcription factors such as SNAI1, SNAI2, and ZEB2, which ultimately result in the resistance to cell-mediated cytotoxicity. Paolicchi et al. suggested that tumor hypoxia is a major contributor to drug resistance and a predisposing factor for increased CSC formation and metastases. 231 Therefore, one promising cancer treatment strategy is to block the proteins related to hypoxia-induced factor (HIF)-1α, EMT, and mitochondria functions, which in turn inhibits the response to hypoxia. In addition, cytokines such as interferon-gamma and tumor necrosis factor-alpha are believed to enhance stromal cell plasticity and contribute to TME. 232

The interaction between TME and TCP can significantly contribute to the genetic heterogeneity. 233 Reynolds et al. demonstrated that the number of genetic mutations arising in cells within tumors is much higher than that in the laboratory culture. 234 Their results provide strong evidence that TME promotes genetic instability during tumor progression. On the other hand, tumor heterogeneity can lead to TME reprogramming and thus give rise to cancer drug resistance. 235 Taken together, the interplay between TCP and TME serves an important role in mediating tumor progression, heterogeneity, and drug resistance.

New strategies for targeting TCP

Preventing initiation of TCP

Strategies that target TCP include intermittent treatments, combination therapies, and targeting the key nodes of phenotypic switching. A study showed that intermittent treatments and off dosing schedules may double the time of melanoma response to vemurafenib. 74 However, intermittent treatment strategies are usually difficult to design as drug resistance may be complex and come from multiple mechanisms other than TCP. 236 , 237 Combination therapies have also been applied to target parallel activation of key signaling pathways such as Hippo/yes-associated protein (YAP), PI3K, and EGFR, 238 , 239 resulting in a significant decrease in the number of residual tumor cells. However, combination therapies usually require more optimized drug administration protocols to maximize responses and limit toxicity due to their complexity.

Other strategies to prevent TCP have focused on inhibiting the key nodes of phenotypic switching genes. Histone demethylases, KDM5A/B and KDM6A, were known to play significant roles in DTP survival. 240 – 242 KDM inhibitors have been developed; however, they are still under assessment for their specificity and efficacy. 243 – 246 DTPs undergo transcriptional adaptation through changing their global chromatin landscape. Another similar strategy that targets the bromodomain and extra terminal domain (BET) BRD4 gene overcame trametinib resistance in triple-negative breast cancer and was efficient both in vitro and in vivo. 110 In basal cell carcinoma, the assessment of inhibition or activation of Wnt and Notch signaling pathways are underperforming in clinical trials to treat pathway-dependent malignancies. 247 Notch-activated tumor cells tend to undergo apoptosis upon vismodegib treatment. Inhibitions of Retinoid X receptor (RXR) pathways using HX531 together with MAPK inhibitors can significantly delay development of resistance to MAPK inhibitors, compared to treatment with MAPK inhibitors alone. 236 Discovery of more drug targets that prevent tumor plasticity will enable the design of treatment strategies.

Targeting the fate of new cells

In addition to preventing the formation of cell plasticity, targeting the emerging drug-resistant new cell identity holds great potential for overcoming tumor plasticity (Fig. 4 ). Transformation from the NSCLC to SCLC usually causes strong drug resistance due to cell plasticity. 248 SCLC cells often lose EGFR expression; therefore, they are resistant to EGFR inhibitors, in contrast to the nontransformed NSCLC (specifically LUAD). Transformed SCLCs were more responsive to platinum-etoposide, similar to de novo SCLC. 67 However, compared to de novo SCLC, transformed SCLC showed a higher response rate to taxanes yet were resistant to checkpoint inhibitor therapy, which was similar to EGFR-mutant LUAD. 249 Recently, molecular studies showed that the growth of some mesenchymal cancer cells depends on the expression of phospholipid glutathione peroxidase 4 (GPX4), and inhibition of GPX4 can profoundly decrease DTP, thus preventing tumor relapse. 250 However, current GPX4 inhibitors are chloroacetamide-containing compounds (such as RLS3), which have been identified to possess only poor pharmacokinetic properties, such as low stability, promiscuity, and bioavailability. The GPX-knockout mouse was lethal, indicating that choosing the therapeutic window that targets this protein is challenging. 251 – 253 Thus, finding drugs that target the new cell identity is necessary for designing therapeutic strategies.

Reversing TCP

TCP can be driven by an inflamed and suppressive TME. Drugs and therapies have been developed against intracellular signaling kinases and extracellular signaling molecules in TME. 254 , 255 Additionally, since epigenetic changes contribute to TCP, targeting those processes could potentially re-sensitize tumor cells to drug treatments.

IL-8

IL-8, a pro-inflammatory cytokine, is known to promote tumor cell remodeling and is involved in regulation of tumor cell stemness, EMT, and therapy resistance in multiple types of tumors. 256 , 257 IL-8 production promotes tumor cells to transform to a mesenchymal phenotype and increase tumor cell migration, leading to metastases. 258 C-X-C chemokine receptor 1 (CXCR1) antagonist therapies have been found to reverse the IL-8 related events. 259 Resistance to PI3K/Akt/mTOR pathway inhibition in hepatocellular carcinoma has been associated with both liver cancer stem cells and a high level of IL-8 expression. Rapamycin, the mTOR inhibitor, was able to decrease the IL-8 expression, thus decrease the resistance to sorafenib. 260 A neutralizing antibody, HuMAX-IL8, was used to deplete IL-8 secretion and treat human TNBC. 261 Another study showed that neutralizing IL-8 can alleviate resistance to erlotinib in NSCLC, thereby enhancing sensitivity in chemotherapy-resistant cells. 262 Inhibition of CXCR2 with SB225002 also alleviated the IL-8-related resistance in sorafenib-resistant ovarian tumor cells. 263

TGF-β

Reversing EMT by blockage of TGF-β signaling is acknowledged as a promising way to reverse TCP, as TGF-β has been widely recognized as the major inducer of EMT. 264 A recent single-cell transcriptome-based study showed that blocking TGF-β1 could restore stromal plasticity in tumors by affecting a subset of interferon-licensed fibroblasts. 265 However, the pleiotropic functions of TGF-β1 in cancer render therapeutic inhibition of this pathway challenging. 266 TGF-β1 inhibition in various combination therapies that target the drug-induced plasticity is under evaluation. 267 Galunisertib (LY2157299 monohydrate), a small molecule inhibitor that inhibits TGFβRI ALK5 kinase, has been used in numerous preclinical trials. 268 Forskolin and cholera toxin have been identified through a drug screen for E-cadherin promoter activation. 269 JMF3086, a dual inhibitor that targets both HDAC and 3-hydroxy-3-methylglutaryl coenzyme A reductase, can restore the sensitivity of NSCLC to EGFR-TKIs (34). A preclinical study showed that galunisertib has the potential to regulate pancreatic cancer cell growth through prevention of TGF-β mediated E-cadherin downregulation. 270 Galunisertib also demonstrated anti-tumor efficacy in patients with pancreatic cancer as well as in a subset of patients with advanced HCC. 271 A recent study also demonstrated that inhibition of TGF-β and leukocyte-associated immunoglobin like receptor-1 (LAIR-1) can remodel TME, thereby enabling programmed-death ligand 1 (PD-L1)-mediated tumor eradication. 272 Dual-blockade of CD73-TGFβ promotes a multifaceted inflammatory environment in TNBC, by diminishing myeloid-derived suppressor cells and M2-macrophages but increasing cytotoxic T cells and activated dendritic cells. 273 These studies and novel drugs have provided strong evidence that blocking TGF-β can reverse TCP, thereby sensitizing tumor cells to targeted or immune-mediated cell death.

EZH2

EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), is the central player in the process of epigenetic gene silencing. EZH2 promotes tumor cell survival, proliferation, EMT, and invasion, as well as drug resistance. 274 Reversible transition between EMT and MET are key aspects of TCP. Interestingly, EZH2 was recently found to support TCP through MET facilitation and tumor colonization. 275 Overexpression of EZH2 was associated with the conversion of prostate adenocarcinoma to neuroendocrine prostate cancer (NEPC), which is a more aggressive variant. 61 , 276 Inhibition of EZH2 can reverse the cell lineage switch, leading to a decrease in neuroendocrine related key factors and restoring the sensitivity of NEPC cells to enzalutamide. Some EZH2 inhibitors (for example, CPI-1205 and Tazemetostat) have entered phase I and II clinical trials for lymphomas and solid tumors. 277 , 278

Other targets and pathways

Other targets and pathways with potential ability to reverse TCP are emerging. Ferroptosis was identified as a new type of programmed cell death that can be harnessed to target drug resistance and EMT. Gagliardi et al. identified that EMT-associated gene expression reprogramming process that determines ferroptotic susceptibility cannot be applied to metastatic-derived cells, but SCL7A11 was a valuable marker to predict the susceptibility. 279 Increased sensitivity to ferroptosis through crosstalk of BACH1 target genes can also impose programmed vulnerability upon cancer cells. 280 Other than ferroptosis, HDAC inhibition was recently found to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma. 281 The Yap-Sox9 axis was recently reported to determine hepatocyte plasticity in hepatocarcinogenesis and could be a promising target. 282 Some other SOX factors have also been considered as promising candidates through proteolysis-targeting chimeric molecules or thalidomide analogues. 283 , 284 An anti-CLDN6 antibody-drug conjugate has been reported to target tumor lineage plasticity. 285 Another recent study showed that blocking the MNK1/2-eIF4E axis could inhibit melanoma phenotypic switching, thereby, sensitizing melanoma to anti–PD-1 immunotherapy. 286 These studies suggest that reversing TCP through other targets could be a propitious future direction.

New therapies for overcoming TCP-induced drug resistance

TCP enables tumor cells to evade traditional anti-tumor therapies. Therefore, agents that block these escape routes can deprive the residual tumor cells of their hiding place and ensure positive treatment results (Fig. 5 ). Fig. 5 Combination treatments for overcoming the tumor cell plasticity induced-therapy resistance. Tumor cells evade targeted treatments by interacting with TME and via EMT programs. Inflammation, hypoxia, and immunosuppressive TME contribute to therapy evasion, and such induced-resistance could be inhibited by a combination treatment including anti-inflammation and anti-hypoxic drugs and immunosuppressive ICB regimens. EMT-modulating agents, on the other hand, could also deal with plasticity induced-therapy resistance as a combination treatment and lead to tumor cell death. TME tumor microenvironment, EMT epithelial-to-mesenchymal transition, ICB immune checkpoint blockade, Rg3 ginseng-extracted 20(R)-Ginsenoside

With immune checkpoint blockade (ICB)

An immunosuppressive TME is formed upon drug exposure as a consequence of the interaction between non-tumor and tumor cells. It is worth mentioning that the expression of immune checkpoint proteins, including programmed cell death 1 receptor (PD-1) and (PD-L1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) contribute significantly to immunosuppression and serve as a bridge between EMT programs and immunosuppression. 287 – 291 A positive correlation between EMT and immune checkpoint proteins was identified in multiple cancer types, including lung, breast, colorectum, oral, and esophageal cancers, 289 , 292 – 297 and a higher expression of these checkpoint molecules indicates worse prognosis in a broad range of cancers. 298 – 300 The functional relationship between immune checkpoint proteins and therapy evasion suggests that a combination treatment with immune checkpoint blockade (ICB) could be promising in developing a new approach against TCP.

Combining targeted therapy with ICB seems feasible according to current practice. Traditional EGFR-TKI was found to interfere with TME, thus laying a theoretical foundation for ICB application in EGFR-TKI-resistant NSCLC, especially in those with upregulated PD-L1 expression. 301 – 303 Moreover, recent studies revealed that dynamic changes occur in TME in response to EGFR-TKIs and suggested that a combination treatment with immune-mediated anticancer approaches could be beneficial. 302 , 304 – 307 EGFR-TKI-ICB combination treatment provided better clinical benefit for NSCLC patients with increased overall response rate (ORR) (41.7% vs 14.3%) and median progression free survival (PFS) (19.5 months vs 1.4 months) in comparison to monotherapy of either pembrolizumab or gefitinib alone. 306 Patients with short EGFR-TKI-PFS may even benefit more from a combination therapy as a second-line treatment. 308 A similar combination strategy was applied in multiple cancer types as a so-called basket trial design. 309 A combination of ICB with antiangiogenic molecular targeted therapy is an attractive approach for treating HCC. According to the IMbrave150 trial, atezolizumab in combination with bevacizumab showed greater benefits compared with sorafenib in advanced HCC patients and suggested that this combination strategy could be used as the first-line standard of care. 310 – 313 Additionally, a combination of ICB with other targeted therapeutic approaches, including ATR kinase inhibition and androgen receptor blockade resulted in synergistic therapeutic response in prostate cancer. 314 – 316

Combining chemotherapy with ICB can be used to extend a synergistic therapeutic effect. 317 , 318 A pooled analysis of three randomized clinical trials indicated that among patients with PD-L1-negative advanced / metastatic NSCLC, efficacy is better with pembrolizumab plus chemotherapy compared with chemotherapy alone. 319 Similar results were obtained in PD-L1-positive NSCLC patients. As indicated by Zhang et al., 320 the combination regimen of toripalimab and pemetrexed/carboplatin was superior to chemotherapy alone. Moreover, an IMpower150 trial showed that a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) led to significant improvement in median overall survival (OS) in chemotherapy-naïve patients with NSCLC. 321 Anti-CTLA-4 ipilimumab was also tested in the treatment for NSCLC in combination with nivolumab and platinum doublet chemotherapy and exhibited clinical value as a first-line treatment. 322 Another phase III clinical trial compared the efficacy of chemotherapy with nivolumab and chemotherapy alone in treatment for advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma, and found that the combination strategy had a benefit of significantly superior OS and PFS. 322 Janjigian et al. 322 proposed that this combination treatment represented a new first-line therapy for patients with upper gastrointestinal tumors. A recent phase III study (KEYNOTE-811) also confirmed that adding pembrolizumab to standard first-line treatment (trastuzumab plus chemotherapy) in advanced gastric or GEJ adenocarcinoma could markedly improve prognosis. 323

Though the basket trial design has greatly improved the clinical outcome of multiple cancer types, our understanding of the underlying mechanisms of the combination regimens remains limited. For example, nab-paclitaxel combined with atezolizumab are able to effectively prolong PFS in patients with metastatic TNBC as shown by the IMPASSION130 trial; however, the combination of paclitaxel with atezolizumab failed in the IMPASSION131 trial. 324 , 325 Single-cell analyses revealed that baseline CXCL13 + T cell largely determined the clinical response in TNBC treatment. 326 Further studies are warranted to explore the exact mechanisms of different combination strategies to be able to pin-point patients with higher therapeutic potential. Furthermore, novel combination methods are emerging. For example, a bioengineered platelet was designed that combines an inner-loaded doxorubicin and outer-anchored anti-PDL1-crosslinked nanogels. This composite design was reported to have the potential to reduce the recurrence and metastasis rate of postsurgical tumors. 327

Despite some optimistic reports, the safety profile of combination therapies with ICB remains poorly understood and controversial. In NSCLC treatment, an increased incidence of interstitial lung disease-like events was observed in the combination treatment of osimertinib and durvalumab in the CAURAL (38%) and TATTON (22%) trial. 328 – 333 Severe hepatotoxicity was observed in another clinical trial (CheckMate370) investigating the combined effect of nivolumab and crizotininb. 306 Similar hepatic and immune-related adverse events were also observed in combined treatment with ICBs in melanoma. 334 – 336

These described studies imply that a combination with ICB can improve therapeutic outcomes for therapy-resistant patients compared with either therapy alone. The clinical feasibility of the combined strategy warrants further exploration, and the safety profile should be carefully documented. Table 1 provides a list of some relevant clinical trials evaluating the combination therapy with ICB mentioned above. Table 1 Relevant clinical trials of combination treatment with ICB Clinical trial (NCT identifier) Conditions Treatment Patients n Phase States NCT02039674 (KEYNOTE-021) NSCLC Pembrolizumab + Ipilimumab + Erlotinib + Gefitinib + Paclitaxel + Carboplatin + Bevacizumab + Pemetrexed Patients with unresectable or metastatic NSCLC 267 I/II Completed NCT02143466 (TATTON) NSCLC Durvalumab + Osimertinib + Selumetinib + Savolitinib NSCLC patients with progression after EGFR-TKIs, T790M positive 344 I Active, not recruiting NCT02366143 (IMpower150) NSCLC Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin Chemotherapy-naïve patients with stage IV non-squamous NSCLC 1202 III Completed NCT02454933 (CAURAL) NSCLC Durvalumab + Osimertinib NSCLC patients with progression after EGFR-TKIs, T790M positive 344 I Active, not recruiting NCT02574078 (CheckMate 370) NSCLC Nivolumab + Erlotinib + Crizotinib + Bevacizumab + Pemetrexed + Nab-Paclitaxel + Paclitaxel + Docetaxel + Gemcitabine + Carboplatin Patients with advanced NSCLC 341 I/II Completed NCT02578680 (KEYNOTE-189) NSCLC Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + Dexamethasone Patients with metastatic non-squamous NSCLC 616 III Active, not recruiting NCT02659059 (CheckMate 568) NSCLC Nivolumab + Ipilimumab + Platinum doublet chemotherapy Stage IV NSCLC 324 II Active, not recruiting NCT02775435 (KEYNOTE-407) NSCLC Pembrolizumab + Paclitaxel+ Nab-paclitaxel + Carboplatin Patients with metastatic non-squamous NSCLC 559 III Active, not recruiting NCT02872116 (CheckMate649) Gastric cancer GEJ cancer Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil Patients with previously untreated advanced or metastatic gastric or GEJ cancer 2031 III Active, not recruiting NCT03434379 (IMbrave150) HCC Atezolizumab + Bevacizumab + Sorafenib Patients with locally advanced or metastatic HCC with no prior systemic treatment 558 III Active, not recruiting NCT03615326 (MK-3475-811/KEYNOTE-811) Gastric neoplasms GEJ adenocarcinoma Pembrolizumab + Cisplatin + 5-FU + Oxaliplatin + Capecitabine + S-1 + Trastuzumab HER2 + patients with advanced gastric or GEJ adenocarcinoma 732 III Active, not recruiting NCT03924050 NSCLC Toripalimab + standard chemotherapy Advanced NSCLC patients with TKI-resistant EGFR-mutated tumors 350 III Unknown NSCLC nonsmall cell lung cancer, EGFR-TKI epidermal growth factor receptor – tyrosine kinase inhibitor, HCC hepatocellular carcinoma, GEJ gastroesophageal junction, 5-FU 5-Fluorouracil, S-1 , tegafur + 5-chloro-2,4-dihydroxypyridine + potassium oxonate, HER-2 human epidermal growth factor receptor 2 All data are from ClinicalTrials.gov, accessed May 2022

With EMT-modulating agents

Because EMT plays an essential role in TCP and drug resistance, EMT-targeting compounds hold great potential as novel drugs in reversing drug resistance. However, investigation in this field is limited.

EMT-TFs play an essential role in TCP, and drugs directly targeting these transcription factors might have the potential to halt or reverse the plasticity and become a novel therapeutic approach to repress drug resistance. However, due to the redundancy of overlapping pathways and multitude of factors, it is hard to target and control TCP effectively. Direct targeting of these EMT-TFs is very challenging and there is not yet known EMT-TF-targeting molecule. 19 Nevertheless, some related molecules involved in redundant EMT pathways have been investigated for clinical use. As a downstream target of YAP and EMT-TF Snail2, anexelekto (AXL) represents an ideal focus of EMT control. 337 , 338 AXL-targeting inhibitors (SGI-7079 / Foretinib [XL-880] / Bemcentinib [BGB324] / 20G7-D9 / MYD1-72) have been reported to have an outstanding synergistic effect with erlotinib in NSCLC 40 , 339 , 340 and advanced pancreatic and ovarian cancers, 337 BRAF inhibitors in melanoma, 341 and temozolomide with radiation in glioblastoma. 342 Multitarget AXL inhibitors like SGI-7079 and sunitinib have also shown prominent clinical value in reversing therapeutic resistance. 40 , 343 , 344 Moreover, secreted clusterin, an EMT-related protein which was shown to be significantly upregulated in EMT progression and HCC migration, is a candidate target for HCC therapy. 345 – 347 An antibody against secreted clusterin, termed as AB-16B5, was assessed in a phase II clinical trial in combination with docetaxel for the treatment of metastatic NSCLC (Table 2 ). Table 2 Ongoing clinical trials of combination treatment with EMT-modulating agents Clinical trial (NCT identifier) Conditions Treatments Patients n Phase States NCT02922777 NSCLC Bemcentinib + Docetaxel Previously treated patients with advanced NSCLC 23 I Active, not recruiting NCT02488408 AML Bemcentinib + Cytarabine + Decitabine Patients with AML 121 I/II Active, not recruiting NCT03184571 NSCLC Bemcentinib + Pembrolizumab Previously treated patients with advanced NSCLC 106 II Recruiting NCT02872259 Melanoma Bemcentinib + Dabrafenib + Trametinib Patients with advanced stage IIIc / IV) melanoma 92 I/II Recruiting NCT04364620 NSCLC AB-16B5 + Docetaxel Previously treated patients with metastatic NSCLC 40 II Recruiting NCT02452008 Prostate Cancer Galunisertib + Enzalutamide Patients with metastatic castration-resistant prostate cancer 60 II Recruiting NCT02672475 Breast cancer Galunisertib + Paclitaxel Patients with metastatic androgen receptor negative or triple negative breast cancer 29 I Active, not recruiting NCT01682187 Nasopharyngeal carcinoma Galunisertib + Gemcitabine + Cisplantin + PD-1 blocking antibody + Radiation Patients with high-risk locoregionally advanced nasopharyngeal carcinoma 206 II Not yet recruiting NCT03206177 Ovarian / Uterine carcinosarcoma Galunisertib + Paclitaxel/Carboplatin Patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary 26 I Active, not recruiting NCT02688712 Rectal adenocarcinoma Galunisertib + Capecitabine + Fluorouracil + Surgery + Radiation Patients with locally advanced rectal adenocarcinoma 50 II Active, not recruiting NCT01582269 Glioblastoma Galunisertib + Lomustine Patients with glioblastoma 180 II Active, not recruiting NCT04396886 Nasopharyngeal carcinoma Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma 37 II Recruiting NCT05005429 Mesothelioma; lung Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Previously treated advanced malignant pleural mesothelioma 47 II Recruiting NCT04349280 Urothelial cancer Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Metastatic or locally advanced urothelial cancer 25 I Active, not recruiting NCT04727541 Biliary tract cancer; Cholangiocarcinoma Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Patients with resectable biliary tract cancer 24 II Recruiting NCT04396535 NSCLC Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Patients with advanced NSCLC 80 II Active, not recruiting NCT05145569 Ovarian cancer Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Patients with metastatic advanced stage ovarian cancer 33 I Not yet recruiting NCT04489940 Breast cancer Bintrafusp alfa (α-PDL1/TGF-βRII fusion protein) Patients with HMGA2 expressing triple negative breast cancer 11 II Active, not recruiting NCT02521844 Solid tumors ETC-1922159 + Pembrolizumab Patients with advanced solid tumors 89 I Recruiting NSCLC non-small cell lung cancer, AML acute myeloid leukemia, HMGA2 high mobility group AT-Hook 2 All data are from ClinicalTrials.gov, accessed May 2022

Inhibition of EMT-related pathways is a theoretically feasible approach to control TCP. TGF-β, a widely accepted key promoter of EMT and sustainer of mesenchymal and CSC states, contributes to the induction of immunosuppressive TME via hijacking Tregs and NK cells. 44 , 45 , 348 A small molecule inhibitor of TGF-β receptor 1 named galunisertib (LY2157299 monohydrate) is attracting attention. One preclinical evaluation of galunisertib showed an inhibition of TGF-β-mediated downregulation of E-cadherin in mouse pancreatic cancer cell line, indicating an anti-EMT effect. 349 A recent study by Song et al. 350 demonstrated a synergistic effect in castration resistant PC using enzalutamide combined with galunisertib. The combinatorial galunisertib treatment successfully sensitized PC cells to traditional androgen deprivation therapy (ADT) and provided a novel therapeutic strategy for control of lineage transdifferentiation. Other studies tested the efficacy of galunisertib in HCC and indicated a prolonged OS using a combination of galunisertib and sorafenib. 351 Melisi et al. 271 stated in a phase Ib/II clinical trial that a galunisertib-gemcitabine combination therapy could significantly improve OS in patients with unresectable pancreatic cancer compared with monotherapy with gemcitabine. The same result was found in myelodysplastic syndromes (MDS); galunsertib treatment was associated with hematologic improvement in patients with signs of blockage of early stem cell differentiation. However, some other clinical trials failed to prove the efficacy of galunisertib in HCC, metastatic pancreatic cancer, or glioma. 352 – 354 Though such novel drugs can manipulate TCP and potentially re-sensitize tumor cells to immune-mediated cell death, further clinical trials are needed to validate their efficacy in different types of tumors. The ongoing clinical trials investigating the combination treatment with galunisertib are shown in Table 2 .

Additionally, a combined immunotherapy of ICB and TGF-β blockade is also promising. In a murine model of metastatic intestinal tumor, the combination of anti-TGF-β and anti-PD-L1 showed an impressive antitumor response compared to either monotherapy. 355 Currently, new approaches for simultaneous inhibition of TGF-β and PD-L1 are under evaluation. Bintrafusp alfa (also known as M7824) is a recently developed anti-PD-L1/ TGF-βRII fusion protein, which showed superior inhibition of tumor growth in multiple murine models. 356 , 357 Other fusion drugs such as anti-CTLA4-TGF-βRII also showed promising efficacy in stimulating antitumor responses. 358 Several early-phase trials showed encouraging clinical efficacy and manageable safety in different types of cancers. 359 – 361 Several ongoing clinical trials are testing the efficacy and safety of bintrafusp alfa (Table 2 ).

Wnt inhibitors including ETC-1922159 and Ipafricept (also known as OMP-54F28) were also employed in clinical control of various types of solid tumors. 362 – 365 Ipafricept combined with chemotherapy showed reasonable tolerance in early-phase clinical trials, and remains a therapeutic target of interest. 363 , 364 , 366 ETC-1922159 is now under assessment in an ongoing clinical trial to test its efficacy as a pembrolizumab combination (Table 2 ).

With other therapy

The close interaction between inflammatory TME and EMT is well established and is regarded as a promising target for therapeutic use. 15 Since TCP drives a highly inflamed TME, neutralizing monoclonal antibodies targeting IL-8 were developed to reverse TCP. HuMax-IL8 (also known as BMS-986253), a neutralizing anti-IL8 antibody that was designed to sequester IL-8 signaling, successfully inhibited the mesenchymal transition in human TNBC cell lines in vitro. Blockade of IL-8 enhanced the tumor cell-killing effect mediated by NK and T cells. Another in vivo study in NSCLC found that IL-8 neutralizing antibodies reversed the tumor plasticity and sensitized tumor cells to erlotinib. Currently, multiple ongoing clinical trials in phase I/II are examining the safety and efficacy of HuMax-IL8 as a combination therapy in various cancer types, including prostate and pancreatic cancer, HCC, NSCLC, and other solid tumors (Table 3 ). SX-682, another novel drug targeting the inflammatory EMT, was proposed to prevent polymorphonuclear (PMN)-MDSC migration and cooperate well with ICB treatment. 367 , 368 Early-phase clinical trials of SX-682 in combination with ICBs (e.g., pembrolizumab and nivolumab) are currently recruiting participants (Table 3 ). Table 3 Ongoing clinical trials of combination treatment with other therapy Clinical trial (NCT identifier) Conditions Treatment Patients n Phase States NCT04848116 SCCHN HuMax-IL8 + Nivolumab SCCHN patients who will undergo surgery. 24 II Recruiting NCT03689699 (MAGIC-8) Prostate cancer HuMax-IL8 + Nivolumab + ADT Patients with prostatic adenocarcinoma 60 Ib/II Active, not recruiting NCT02451982 Pancreatic Cancer HuMax-IL8 + Nivolumab Patients with resectable pancreatic adenocarcinoma 76 II Recruiting NCT04050462 HCC HuMax-IL8 + Nivolumab Advanced HCC patients 74 II Recruiting NCT03400332 Advanced cancers HuMax-IL8 + Nivolumab + Ipilimumab Patients with advanced solid tumor 372 I/II Recruiting NCT04123379 NSCLC or HCC HuMax-IL8 + Nivolumab NSCLC or HCC patients 50 II Recruiting NCT04572451 Unresectable Solid Tumors HuMax-IL8 + Nivolumab + SBRT Patients with advanced / metastatic / unresectable solid tumors progressed on standard therapies 50 I Recruiting NCT03161431 Melanoma SX-682 + Pembrolizumab Patients with metastatic melanoma 77 I Recruiting NCT04599140 (STOPTRAFFIC-1) Colorectal cancer SX-682 + Nivolumab RAS-mutated, microsatellite stable, unresectable or metastatic Colorectal Cancer 53 I/II Recruiting NCT04477343 Pancreatic cancer SX-682 + Nivolumab Patients with metastatic pancreatic ductal adenocarcinoma 20 I Recruiting SCCHN Head and neck squamous cell carcinoma, ADT androgen deprivation therapy, HCC hepatocellular carcinoma, NSCLC non-small cell lung cancer, SBRT stereotactic body radiotherapy All data are from ClinicalTrials.gov, accessed May 2022

Hypoxia signaling contributes significantly to EMT and subsequent therapy resistance. Hypoxia-induced factor (HIF), a transcriptional regulator, was reported to be recruited to the hypoxia-responsive element of several EMT-related genes, including Twist, Snail, Vimentin, and TGF-β. 369 HIF-1α promoted EMT via multiple signaling pathways, including PI3K/Akt, Notch, Wnt, and NF-κB. 345 , 370 Treatments targeting hypoxia pathway are deemed as promising blockades against TCP. For example, by blocking the nuclear translocation of HIF-1α, 6-gingerol successfully inhibits the EMT pathway and suppresses proliferation and metastasis of lung cancer. 369 Salidroside enhances antitumor efficacy of platinum drugs in HCC by promoting the degradation of HIF-1α, thereby inhibiting the EMT of HCC cells. 371 Similarly in lung cancer, by inhibiting hypoxia-activated NF-κB signaling pathway and EMT, a ginseng-extracted 20( R )-Ginsenoside (Rg3) increases the susceptibility of cancer cells to cisplatin treatment. 345

Conclusion and perspectives

Here, we present a comprehensive description of TCP development and cancer cell evasion from targeted therapy. We delineate the non-genetic mechanisms of targeted drug-induced TCP in various types of tumors and provide insights into TCP contribution to acquired drug resistance. Owing to the rapid development of experimental techniques, dynamic changes of tumor cells in response to treatments can be observed in high resolution images. The ceaseless change of tumor cells indicates that living things even as simple as single cells show amazing adaptability under ambient pressure. Continuous monitoring of phenotypic switching can be of great help in designing specific dynamic therapeutic regimens and developing such monitoring techniques is worth exploring. We have been able to look into some pathways, like EMT, CSC, and transdifferentiation, that facilitate transformation of tumor cells; however, we still cannot visualize all the mechanisms contributing to TCP.

Research and development for new treatment is never-ending. As an old saying goes, a coin has two sides. In spite of TCP-related therapy escape, TCP also allows therapeutic reprogramming and possibly reversal of tissue attrition. In this review, we summarize new therapeutic strategies that aim to inhibit or reverse TCP and discuss related combination treatment regimens. We note that regulation of plasticity-related TME with ICB or direct imposition of EMT-modulating agents will not bring revolutionary improvement in cancer treatment. However, each small step forward against cancer is worth trying, and the concept of TCP remains valuable for further development of novel therapeutic strategies. Inhibition of unexpected TCP is theoretically feasible by holding the tumor cell unchanged. On the other hand, effective manipulation of TCP also holds great potential, and converting diverse tumor cells into a unified and susceptible state could be an alternative. The basket trial design should be continued to probe new treatment opportunities for different types of cancers, and special attention should be given to searching for new targets to better manipulate TCP.

As for future research on TCP, modern technologies could be of great help. For example, omics technique and capacity of dealing with “big data” has largely broadened our knowledge of the molecular landscape of tumor tissues. Recently developed technologies could enable a simultaneous acquisition of multiple omics data at a single-cell level, and several analytic models have been established to interpret the high-dimensional multimodal data. 372 , 373 Single-cell level multi-omics could precisely trace the therapy-induced responses of each cell in heterogeneous tumors from the aspects of transcriptomics, proteomics, epigenomics, even in combination with their spatial distribution. The innovative analytical modalities provide deep and comprehensive information at single-cell resolution and could help to explore yet unrecognized cellular activity both intracellularly and intercellularly. In addition, single-cell techniques could also help to identify biomarkers to determine TCP, tumor response to targeted therapy, as well as prognosis. 374 Artificial intelligence could also be employed to capture the underlying regularities of such an unwieldly mass of data. It was expected that one day, with the help of big data and the corresponding interpreting capacity, complete cures could be achieved by personalized treatment strategies decided by molecules at single-cell level.

In the face of such capricious, unpredictable, and threatening disease, scientific research will be always on the way to distill the complexity of cancer into an increasingly logical science. The attempts to get a better understanding of TCP in targeted therapy hold great promise for future blockade against therapy evasion, which may promote realization of long-lasting curative effects and even complete cure in cancer patients. Ongoing clinical trials using conventional treatments combined with plasticity-regulating treatment also indicate new opportunities for achieving the goal of complete cancer cure.

Supplementary information

Duplicate checking of papers Editing Certificate1 Editing Certificate2

These authors contributed equally: Zhen-Duo Shi, Kun Pang, Zhuo-Xun Wu, Yang Dong.

Supplementary information

The online version contains supplementary material available at 10.1038/s41392-023-01383-x.

Acknowledgements

We thank Figdraw ( www.figdraw.com ) for providing us the tools for the figure presentation. We appreciate the assistance received in data processing and consultation from Intanx Life Co. Ltd. (Shanghai). We also thank KRGENE (Shanghai KR Pharmtech, Inc., Ltd.) and Fountanx Biomedical (Shanghai) Co., Ltd. for valuable comments and suggestions on the manuscript.

Author contributions

Conception and design of the research: Z.-D.S. Drafting the manuscript: K.P., Z.-X.W. and Y.D. Production of figures in the article: L.H., J.-X.Q. and W.W. Manuscript revision for important intellectual content: Z.-S.C. and C.-H.H. All authors have read and approved the article.

Funding

This work was supported by the National Natural Science Foundation of China (12271467,81774089, 82004110); the Jiangsu Province Key Research and Development Program (BE2020758, BE2019637); the Xuzhou Medical Outstanding Talents (Xuzhou Health Education Research [2017] No.22); the Jiangsu Medical Innovation Team (CXTDA2017048); the Key Projects of Xuzhou Science and Technology Plan (KC19075); the Xuzhou Clinical Medicine Expert Team Project (2018TD004); the Xuzhou Medical Key Talents Project (XWRCHT20220055); and the Xuzhou Medical Reserve Talents Project (XWRCHT20220009, XWRCHT20220012).

Competing interests

The authors declare no competing interests.

References

1. Quintanal-Villalonga A Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation J. Hematol. Oncol. 2021 14 170 10.1186/s13045-021-01186-z 34656143 PMC8520275

2. Paksa A Rajagopal J The epigenetic basis of cellular plasticity Curr. Opin. Cell Biol. 2017 49 116 122 10.1016/j.ceb.2018.01.003 29413970 PMC5949887

3. Waddington CH Embryology, epigenetics and biogenetics Nature 1956 177 1241 1241 10.1038/1771241a0

4. Tata PR Rajagopal J Cellular plasticity: 1712 to the present day Curr. Opin. Cell Biol. 2016 43 46 54 10.1016/j.ceb.2016.07.005 27485353 PMC5154913

5. Castranova D Live Imaging of Intracranial Lymphatics in the Zebrafish Circ. Res. 2021 128 42 58 10.1161/CIRCRESAHA.120.317372 33135960 PMC7790877

6. Bower NI Mural lymphatic endothelial cells regulate meningeal angiogenesis in the zebrafish Nat. Neurosci. 2017 20 774 783 10.1038/nn.4558 28459441

7. Gunawan F Gentile A Gauvrit S Stainier DYR Bensimon-Brito A Nfatc1 Promotes Interstitial Cell Formation During Cardiac Valve Development in Zebrafish Circ. Res. 2020 126 968 984 10.1161/CIRCRESAHA.119.315992 32070236

8. Matsumoto T Wakefield L Tarlow BD Grompe M In Vivo Lineage Tracing of Polyploid Hepatocytes Reveals Extensive Proliferation during Liver Regeneration Cell Stem Cell 2020 26 34 47 e33 10.1016/j.stem.2019.11.014 31866222 PMC7204404

9. Chen F Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration Cell Stem Cell 2020 26 27 33 e24 10.1016/j.stem.2019.11.001 31866223 PMC8009755

10. Schaub JR De novo formation of the biliary system by TGFbeta-mediated hepatocyte transdifferentiation Nature 2018 557 247 251 10.1038/s41586-018-0075-5 29720662 PMC6597492

11. Takahashi K Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 2007 131 861 872 10.1016/j.cell.2007.11.019 18035408

12. Saha S Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFkappaB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells Cancer Res 2016 76 2000 2012 10.1158/0008-5472.CAN-15-1360 26842876

13. Francescangeli F A pre-existing population of ZEB2(+) quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer J. Exp. Clin. Cancer Res. 2020 39 2 10.1186/s13046-019-1505-4 31910865 PMC6947904

14. Boumahdi S de Sauvage FJ The great escape: tumour cell plasticity in resistance to targeted therapy Nat. Rev. Drug Discov. 2020 19 39 56 10.1038/s41573-019-0044-1 31601994

15. Qin S Emerging role of tumor cell plasticity in modifying therapeutic response Signal Transduct. Target Ther. 2020 5 228 10.1038/s41392-020-00313-5 33028808 PMC7541492

16. Shaffer SM Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance Nature 2017 546 431 435 10.1038/nature22794 28607484 PMC5542814

17. Kurata T Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance Ann. Oncol. 2004 15 173 174 10.1093/annonc/mdh006 14679138

18. Davies AH Beltran H Zoubeidi A Cellular plasticity and the neuroendocrine phenotype in prostate cancer Nat. Rev. Urol. 2018 15 271 286 10.1038/nrurol.2018.22 29460922

19. Horn LA Fousek K Palena C Tumor Plasticity and Resistance to Immunotherapy Trends Cancer 2020 6 432 441 10.1016/j.trecan.2020.02.001 32348738 PMC7192950

20. Zhu X Chen L Liu L Niu X EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies Front. Oncol. 2019 9 1044 10.3389/fonc.2019.01044 31681582 PMC6798878

21. Shibue T Weinberg RA EMT, CSCs, and drug resistance: the mechanistic link and clinical implications Nat. Rev. Clin. Oncol. 2017 14 611 629 10.1038/nrclinonc.2017.44 28397828 PMC5720366

22. Hass R von der Ohe J Ungefroren H The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes Cancers (Basel) 2020 12 3674 10.3390/cancers12123674 33297508 PMC7762343

23. Gregory PA An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition Mol. Biol. Cell 2011 22 1686 1698 10.1091/mbc.e11-02-0103 21411626 PMC3093321

24. Siemens H miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions Cell Cycle 2011 10 4256 4271 10.4161/cc.10.24.18552 22134354

25. Martin P Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition Am. J. Pathol. 2011 179 422 435 10.1016/j.ajpath.2011.03.035 21703421 PMC3123810

26. Yamasaki J MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer Cancer Sci. 2022 113 916 925 10.1111/cas.15244 34931404 PMC8898706

27. Luond F Distinct contributions of partial and full EMT to breast cancer malignancy Dev. Cell 2021 56 3203 3221 e3211 10.1016/j.devcel.2021.11.006 34847378

28. Pastushenko I Identification of the tumour transition states occurring during EMT Nature 2018 556 463 468 10.1038/s41586-018-0040-3 29670281

29. Lytle NK Barber AG Reya T Stem cell fate in cancer growth, progression and therapy resistance Nat. Rev. Cancer 2018 18 669 680 10.1038/s41568-018-0056-x 30228301 PMC8388042

30. Panchy N Azeredo-Tseng C Luo M Randall N Hong T Integrative Transcriptomic Analysis Reveals a Multiphasic Epithelial-Mesenchymal Spectrum in Cancer and Non-tumorigenic Cells Front. Oncol. 2019 9 1479 10.3389/fonc.2019.01479 32038999 PMC6987415

31. Bakir B Chiarella AM Pitarresi JR Rustgi AK EMT, MET, Plasticity, and Tumor Metastasis Trends Cell Biol. 2020 30 764 776 10.1016/j.tcb.2020.07.003 32800658 PMC7647095

32. Yang J Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 2004 117 927 939 10.1016/j.cell.2004.06.006 15210113

33. Addison JB Functional Hierarchy and Cooperation of EMT Master Transcription Factors in Breast Cancer Metastasis Mol. Cancer Res 2021 19 784 798 10.1158/1541-7786.MCR-20-0532 33500360 PMC8137545

34. Krebs AM The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer Nat. Cell Biol. 2017 19 518 529 10.1038/ncb3513 28414315

35. Lambert AW Pattabiraman DR Weinberg RA Emerging Biological Principles of Metastasis Cell 2017 168 670 691 10.1016/j.cell.2016.11.037 28187288 PMC5308465

36. Esposito M Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis Nat. Cell Biol. 2019 21 627 639 10.1038/s41556-019-0309-2 30988423 PMC6556210

37. Pastushenko I Blanpain C EMT Transition States during Tumor Progression and Metastasis Trends Cell Biol. 2019 29 212 226 10.1016/j.tcb.2018.12.001 30594349

38. De Angelis ML Francescangeli F Zeuner A Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities Cancers (Basel) 2019 11 1569 10.3390/cancers11101569 31619007 PMC6826533

39. Culig Z Epithelial mesenchymal transition and resistance in endocrine-related cancers Biochim Biophys. Acta Mol. Cell Res 2019 1866 1368 1375 10.1016/j.bbamcr.2019.05.003 31108117

40. Byers LA An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance Clin. Cancer Res 2013 19 279 290 10.1158/1078-0432.CCR-12-1558 23091115 PMC3567921

41. Paulitschke V Proteomic identification of a marker signature for MAPKi resistance in melanoma EMBO J. 2019 38 e95874 10.15252/embj.201695874 31267558 PMC6669927

42. Farmer P A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat. Med. 2009 15 68 74 10.1038/nm.1908 19122658

43. Zhang M Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation J. Cell. Physiol. 2019 234 6361 6370 10.1002/jcp.27369 30229902

44. Liu M Li S Li MO TGF-beta Control of Adaptive Immune Tolerance: A Break From Treg Cells Bioessays 2018 40 e1800063 10.1002/bies.201800063 30159904 PMC6300063

45. Viel S TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway Sci. Signal 2016 9 ra19 10.1126/scisignal.aad1884 26884601

46. Saxena M Stephens MA Pathak H Rangarajan A Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters Cell Death Dis. 2011 2 e179 10.1038/cddis.2011.61 21734725 PMC3199722

47. Merrell AJ Stanger BZ Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style Nat. Rev. Mol. Cell Biol. 2016 17 413 425 10.1038/nrm.2016.24 26979497 PMC5818993

48. Rubin MA Bristow RG Thienger PD Dive C Imielinski M Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers Mol. Cell 2020 80 562 577 10.1016/j.molcel.2020.10.033 33217316 PMC8399907

49. Fang D A tumorigenic subpopulation with stem cell properties in melanomas Cancer Res 2005 65 9328 9337 10.1158/0008-5472.CAN-05-1343 16230395

50. Tang JY Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Lancet Oncol. 2016 17 1720 1731 10.1016/S1470-2045(16)30566-6 27838224

51. Sofen H A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma J. Am. Acad. Dermatol. 2015 73 99 105 e101 10.1016/j.jaad.2015.03.013 25913533

52. Biehs B A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition Nature 2018 562 429 433 10.1038/s41586-018-0596-y 30297801

53. Sanchez-Danes A A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy Nature 2018 562 434 438 10.1038/s41586-018-0603-3 30297799 PMC6295195

54. Konieczkowski DJ Johannessen CM Garraway LA A Convergence-Based Framework for Cancer Drug Resistance Cancer Cell 2018 33 801 815 10.1016/j.ccell.2018.03.025 29763622 PMC5957297

55. Zou M Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer Cancer Disco. 2017 7 736 749 10.1158/2159-8290.CD-16-1174 PMC5501744 28411207

56. Conteduca V Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis NPJ Precis Oncol. 2021 5 76 10.1038/s41698-021-00211-1 34385567 PMC8361159

57. Epstein JI Proposed morphologic classification of prostate cancer with neuroendocrine differentiation Am. J. Surg. Pathol. 2014 38 756 767 10.1097/PAS.0000000000000208 24705311 PMC4112087

58. Conteduca V Clinical features of neuroendocrine prostate cancer Eur. J. Cancer 2019 121 7 18 10.1016/j.ejca.2019.08.011 31525487 PMC6803064

59. Wang Y Molecular events in neuroendocrine prostate cancer development Nat. Rev. Urol. 2021 18 581 596 10.1038/s41585-021-00490-0 34290447 PMC10802813

60. Quintanal-Villalonga A Lineage plasticity in cancer: a shared pathway of therapeutic resistance Nat. Rev. Clin. Oncol. 2020 17 360 371 10.1038/s41571-020-0340-z 32152485 PMC7397755

61. Ku SY Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance Science 2017 355 78 83 10.1126/science.aah4199 28059767 PMC5367887

62. Mu P SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer Science 2017 355 84 88 10.1126/science.aah4307 28059768 PMC5247742

63. Svensson C REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer Nucleic Acids Res 2014 42 999 1015 10.1093/nar/gkt921 24163104 PMC3902919

64. Merkens L Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation J. Exp. Clin. Cancer Res. 2022 41 46 10.1186/s13046-022-02255-y 35109899 PMC8808994

65. Cyrta J Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity Nat. Commun. 2020 11 5549 10.1038/s41467-020-19328-1 33144576 PMC7642293

66. Balanis NG Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies Cancer Cell 2019 36 17 34.e17 10.1016/j.ccell.2019.06.005 31287989 PMC6703903

67. Ferrer L A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics J. Thorac. Oncol. 2019 14 130 134 10.1016/j.jtho.2018.08.2028 30217489

68. Oser MG Niederst MJ Sequist LV Engelman JA Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin Lancet Oncol. 2015 16 e165 172 10.1016/S1470-2045(14)71180-5 25846096 PMC4470698

69. Lee JK Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas J. Clin. Oncol. 2017 35 3065 3074 10.1200/JCO.2016.71.9096 28498782

70. Offin M Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes J. Thorac. Oncol. 2019 14 1784 1793 10.1016/j.jtho.2019.06.002 31228622 PMC6764905

71. Mahadevan NR Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity Cancer Disco. 2021 11 1952 1969 10.1158/2159-8290.CD-20-0913 PMC8338750 33707236

72. Shaurova T Zhang L Goodrich DW Hershberger PA Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer Front Genet 2020 11 281 10.3389/fgene.2020.00281 32292420 PMC7121227

73. Prasetyanti PR Medema JP Intra-tumor heterogeneity from a cancer stem cell perspective Mol. Cancer 2017 16 41 10.1186/s12943-017-0600-4 28209166 PMC5314464

74. Das M Law S Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence Int. J. Biochem. Cell Biol. 2018 103 115 124 10.1016/j.biocel.2018.08.011 30153480

75. Dirkse A Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment Nat. Commun. 2019 10 1787 10.1038/s41467-019-09853-z 30992437 PMC6467886

76. Kusienicka A Heme Oxygenase-1 Has a Greater Effect on Melanoma Stem Cell Properties Than the Expression of Melanoma-Initiating Cell Markers Int. J. Mol. Sci. 2022 23 3596 10.3390/ijms23073596 35408953 PMC8998882

77. Lee WK Regulation of cancer stem cell activity by thyroid hormone receptor β Oncogene 2022 41 2315 2325 10.1038/s41388-022-02242-9 35256781 PMC9018601

78. Thankamony AP Saxena K Murali R Jolly MK Nair R Cancer Stem Cell Plasticity - A Deadly Deal Front Mol. Biosci. 2020 7 79 10.3389/fmolb.2020.00079 32426371 PMC7203492

79. Correia C Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View Front Cell Dev. Biol. 2022 10 752326 10.3389/fcell.2022.752326 35359437 PMC8962639

80. Santoro A Vlachou T Carminati M Pelicci PG Mapelli M Molecular mechanisms of asymmetric divisions in mammary stem cells EMBO Rep. 2016 17 1700 1720 10.15252/embr.201643021 27872203 PMC5283594

81. Peiris-Pagès M Martinez-Outschoorn UE Pestell RG Sotgia F Lisanti MP Cancer stem cell metabolism Breast Cancer Res 2016 18 55 10.1186/s13058-016-0712-6 27220421 PMC4879746

82. Najafi M Mortezaee K Ahadi R Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance Life Sci. 2019 231 116520 10.1016/j.lfs.2019.05.076 31158379

83. Wu M Imaging hematopoietic precursor division in real time Cell Stem Cell 2007 1 541 554 10.1016/j.stem.2007.08.009 18345353 PMC2267762

84. Liu D Asymmetric Division Gene Neurl2 Mediates Twist2 Regulation of Self-Renewal of Mouse Lewis Lung Cancer Stem Cells J. Cancer 2019 10 3381 3388 10.7150/jca.31553 31293641 PMC6603408

85. Poli V Fagnocchi L Zippo A Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics Stem Cells Int 2018 2018 4598195 10.1155/2018/4598195 29853913 PMC5954911

86. Benboubker V Boivin F Dalle S Caramel J Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma Front. Immunol. 2022 13 873116 10.3389/fimmu.2022.873116 35432344 PMC9012258

87. Grillet F Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture Gut 2017 66 1802 1810 10.1136/gutjnl-2016-311447 27456153 PMC5595103

88. Lambert AW Weinberg RA Linking EMT programmes to normal and neoplastic epithelial stem cells Nat. Rev. Cancer 2021 21 325 338 10.1038/s41568-021-00332-6 33547455

89. Obermayr E Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer J. Pers. Med 2021 11 1225 10.3390/jpm11111225 34834576 PMC8620949

90. Jiang W Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy Theranostics 2022 12 2987 3006 10.7150/thno.71693 35401832 PMC8965496

91. Hirschmann-Jax C A distinct “side population” of cells with high drug efflux capacity in human tumor cells Proc. Natl Acad. Sci. U. S. A. 2004 101 14228 14233 10.1073/pnas.0400067101 15381773 PMC521140

92. Xu J Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy Clin. Cancer Res 2022 28 1979 1990 10.1158/1078-0432.CCR-20-0468 35140124 PMC9064967

93. Ouellette MM Zhou S Yan Y Cell Signaling Pathways That Promote Radioresistance of Cancer Cells Diagnostics (Basel) 2022 12 656 10.3390/diagnostics12030656 35328212 PMC8947583

94. Wozny AS Involvement of HIF-1alpha in the Detection, Signaling, and Repair of DNA Double-Strand Breaks after Photon and Carbon-Ion Irradiation Cancers (Basel) 2021 13 3833 10.3390/cancers13153833 34359734 PMC8345054

95. Zaretsky JM Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma N. Engl. J. Med. 2016 375 819 829 10.1056/NEJMoa1604958 27433843 PMC5007206

96. Su S CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness Cell 2018 172 841 856 e816 10.1016/j.cell.2018.01.009 29395328

97. Wang X Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression Cell Stem Cell 2018 22 514 528.e515 10.1016/j.stem.2018.03.011 29625067 PMC5947947

98. Tammela T A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma Nature 2017 545 355 359 10.1038/nature22334 28489818 PMC5903678

99. Guo L Lee YT Zhou Y Huang Y Targeting epigenetic regulatory machinery to overcome cancer therapy resistance Semin. Cancer Biol. 2021 83 487 502 10.1016/j.semcancer.2020.12.022 33421619 PMC8257754

100. Tan T Epigenetic modification regulates tumor progression and metastasis through EMT (Review) Int. J. Oncol. 2022 60 70 10.3892/ijo.2022.5360 35445731 PMC9084613

101. Allis CD Jenuwein T The molecular hallmarks of epigenetic control Nat. Rev. Genet. 2016 17 487 500 10.1038/nrg.2016.59 27346641

102. Yosifov DY DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy Sci. Data 2020 7 133 10.1038/s41597-020-0456-0 32358561 PMC7195470

103. Cardenas H Methylomic Signatures of High Grade Serous Ovarian Cancer Epigenetics 2021 16 1201 1216 10.1080/15592294.2020.1853402 33289590 PMC8813084

104. Selli C Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours Breast Cancer Res 2019 21 2 10.1186/s13058-018-1089-5 30616553 PMC6323855

105. Stone A DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer Nat. Commun. 2015 6 7758 10.1038/ncomms8758 26169690 PMC4510968

106. Reina-Campos M Increased Serine and One-Carbon Pathway Metabolism by PKClambda/iota Deficiency Promotes Neuroendocrine Prostate Cancer Cancer Cell 2019 35 385 400 e389 10.1016/j.ccell.2019.01.018 30827887 PMC6424636

107. Nachiyappan A Gupta N Taneja R EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms FEBS J. 2022 289 1329 1351 10.1111/febs.16334 34954891

108. Wang Z SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy Cancer Cell 2020 37 834 849 e813 10.1016/j.ccell.2020.04.014 32442403 PMC8187079

109. Knoechel B An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia Nat. Genet. 2014 46 364 370 10.1038/ng.2913 24584072 PMC4086945

110. Zawistowski JS Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex Cancer Disco. 2017 7 302 321 10.1158/2159-8290.CD-16-0653 PMC5340640 28108460

111. Zheng X Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer Nature 2015 527 525 530 10.1038/nature16064 26560028 PMC4849281

112. Yochum ZA Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer Oncogene 2019 38 656 670 10.1038/s41388-018-0482-y 30171258 PMC6358506

113. Dai C Heemers H Sharifi N Androgen Signaling in Prostate Cancer Cold Spring Harb. Perspect. Med. 2017 7 a030452 10.1101/cshperspect.a030452 28389515 PMC5580512

114. Masiello D Cheng S Bubley GJ Lu ML Balk SP Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor J. Biol. Chem. 2002 277 26321 26326 10.1074/jbc.M203310200 12015321

115. Ito Y Sadar MD Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens Res Rep. Urol. 2018 10 23 32 29497605 10.2147/RRU.S157116 PMC5818862

116. Fujita K Nonomura N Role of Androgen Receptor in Prostate Cancer: A Review World J. Mens. Health 2019 37 288 295 10.5534/wjmh.180040 30209899 PMC6704300

117. Lee H Jeong AJ Ye SK Highlighted STAT3 as a potential drug target for cancer therapy BMB Rep. 2019 52 415 423 10.5483/BMBRep.2019.52.7.152 31186087 PMC6675244

118. Wang H MicroRNA-181d-5p-Containing Exosomes Derived from CAFs Promote EMT by Regulating CDX2/HOXA5 in Breast Cancer Mol. Ther. Nucleic Acids 2020 19 654 667 10.1016/j.omtn.2019.11.024 31955007 PMC6970169

119. East MP Johnson GL Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition J. Biol. Chem. 2022 298 101525 10.1016/j.jbc.2021.101525 34958800 PMC8888345

120. Wessely A Steeb T Berking C Heppt MV How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance Int. J. Mol. Sci. 2021 22 5761 10.3390/ijms22115761 34071193 PMC8198848

121. Yang C Tian C Hoffman TE Jacobsen NK Spencer SL Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling Nat. Commun. 2021 12 1747 10.1038/s41467-021-21549-x 33741929 PMC7979728

122. Sachindra New role of ID3 in melanoma adaptive drug-resistance Oncotarget 2017 8 110166 110175 10.18632/oncotarget.22698 29299138 PMC5746373

123. Sun C Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature 2014 508 118 122 10.1038/nature13121 24670642

124. Hartman ML Sztiller-Sikorska M Gajos-Michniewicz A Czyz M Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity Cells 2020 9 142 10.3390/cells9010142 31936151 PMC7017165

125. Salaritabar A Targeting Hedgehog signaling pathway: Paving the road for cancer therapy Pharmacol. Res. 2019 141 466 480 10.1016/j.phrs.2019.01.014 30639373

126. Choi JI Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells Cancer Lett. 2021 498 42 53 10.1016/j.canlet.2020.10.012 33188841

127. Sacchetti A Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer Elife 2021 10 e61461 10.7554/eLife.61461 34036938 PMC8192123

128. Yang X Wnt signaling in triple-negative breast cancers: Its roles in molecular subtyping and cancer cell stemness and its crosstalk with non-coding RNAs Life Sci. 2022 300 120565 10.1016/j.lfs.2022.120565 35461838

129. Giroux-Leprieur E Costantini A Ding VW He B Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance Int. J. Mol. Sci. 2018 19 2835 10.3390/ijms19092835 30235830 PMC6165231

130. Bhateja P Cherian M Majumder S Ramaswamy B The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer? Cancers (Basel) 2019 11 1126 10.3390/cancers11081126 31394751 PMC6721501

131. Monkkonen T Lewis MT New paradigms for the Hedgehog signaling network in mammary gland development and breast Cancer Biochim Biophys. Acta Rev. Cancer 2017 1868 315 332 10.1016/j.bbcan.2017.06.003 28624497 PMC5567999

132. Song J Noncoding RNAs related to the hedgehog pathway in cancer: clinical implications and future perspectives Mol. Cancer 2022 21 115 10.1186/s12943-022-01591-z 35581586 PMC9112456

133. Cortes JE Gutzmer R Kieran MW Solomon JA Hedgehog signaling inhibitors in solid and hematological cancers Cancer Treat. Rev. 2019 76 41 50 10.1016/j.ctrv.2019.04.005 31125907

134. Xie Y Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma Oncogene 2020 39 922 934 10.1038/s41388-019-1037-6 31576013

135. Merchant AA Matsui W Targeting Hedgehog-a cancer stem cell pathway Clin. Cancer Res 2010 16 3130 3140 10.1158/1078-0432.CCR-09-2846 20530699 PMC2888641

136. Cazet AS Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer Nat. Commun. 2018 9 2897 10.1038/s41467-018-05220-6 30042390 PMC6057940

137. Barzegar Behrooz A Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma Int. J. Mol. Sci. 2022 23 1353 10.3390/ijms23031353 35163279 PMC8836096

138. Wang J Cinobufacini Inhibits Colon Cancer Invasion and Metastasis via Suppressing Wnt/β-Catenin Signaling Pathway and EMT Am. J. Chin. Med 2020 48 703 718 10.1142/S0192415X20500354 32329642

139. Moon JH Lee SH Lim YC Wnt/β-catenin/Slug pathway contributes to tumor invasion and lymph node metastasis in head and neck squamous cell carcinoma Clin. Exp. Metastasis 2021 38 163 174 10.1007/s10585-021-10081-3 33630219

140. Sun Y Song GD Sun N Chen JQ Yang SS Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis Oncol. Lett. 2014 7 1936 1940 10.3892/ol.2014.2037 24932263 PMC4049749

141. Tian S SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway Aging (Albany N. Y.) 2020 12 3574 3593 10.18632/aging.102831 PMC7066881 32091407

142. Howe LR Watanabe O Leonard J Brown AM Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation Cancer Res 2003 63 1906 1913 12702582

143. Zhu QQ Ma C Wang Q Song Y Lv T The role of TWIST1 in epithelial-mesenchymal transition and cancers Tumour Biol. 2016 37 185 197 10.1007/s13277-015-4450-7 26602382

144. Liu X Cellular retinol binding protein-1 inhibits cancer stemness via upregulating WIF1 to suppress Wnt/beta-catenin pathway in hepatocellular carcinoma BMC Cancer 2021 21 1224 10.1186/s12885-021-08967-2 34775955 PMC8590789

145. Suda T Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma Int. J. Mol. Sci. 2022 23 2801 10.3390/ijms23052801 35269944 PMC8911428

146. Rong L Xu Y Zhang K Jin L Liu X HNRNPA2B1 inhibited SFRP2 and activated Wnt-beta/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma Pathol. Res. Pract. 2022 233 153794 10.1016/j.prp.2022.153794 35364458

147. Vermeulen L Wnt activity defines colon cancer stem cells and is regulated by the microenvironment Nat. Cell Biol. 2010 12 468 476 10.1038/ncb2048 20418870

148. Deldar Abad Paskeh M Mirzaei S Ashrafizadeh M Zarrabi A Sethi G Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways J. Hepatocell. Carcinoma 2021 8 1415 1444 10.2147/JHC.S336858 34858888 PMC8630469

149. Zhan T MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer Nat. Commun. 2019 10 2197 10.1038/s41467-019-09898-0 31097693 PMC6522484

150. Debeb BG Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling Stem Cells 2012 30 2366 2377 10.1002/stem.1219 22961641 PMC4545658

151. De Santis F BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer Cell. Oncol. (Dordr.) 2022 45 257 274 10.1007/s13402-022-00663-y 35357654 PMC12978040

152. Buyuk B Jin S Ye K Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis Cell. Mol. Bioeng. 2022 15 1 13 10.1007/s12195-021-00694-9 35096183 PMC8761190

153. Wang LL Wan XY Liu CQ Zheng FM NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties Mol. Med. 2022 28 49 10.1186/s10020-022-00480-x 35508987 PMC9066784

154. Koba H NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment Transl. Lung Cancer Res 2021 10 4161 4173 10.21037/tlcr-21-536 35004247 PMC8674607

155. Anobile DP Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma Expert Rev. Clin. Pharmacol. 2022 15 305 322 10.1080/17512433.2022.2074835 35533249

156. Uramoto H Shimokawa H Hanagiri T Kuwano M Ono M Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma Lung Cancer 2011 73 361 365 10.1016/j.lungcan.2011.01.008 21315472

157. Xie M Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells J. Cell. Biochem. 2012 113 1501 1513 22173954 10.1002/jcb.24019

158. Shen Y Estrogen receptor alpha-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer Cell Commun. Signal 2019 17 50 10.1186/s12964-019-0367-x 31122254 PMC6533681

159. von Arx C Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms J. Clin. Med 2019 8 1277 10.3390/jcm8091277 31443481 PMC6780206

160. Natsuizaka M Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma Nat. Commun. 2017 8 1758 10.1038/s41467-017-01500-9 29170450 PMC5700926

161. Zeng D Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells Int. J. Cancer 2020 147 490 504 10.1002/ijc.32911 32020593

162. Saad S Stanners SR Yong R Tang O Pollock CA Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor Int. J. Biochem. Cell Biol. 2010 42 1115 1122 10.1016/j.biocel.2010.03.016 20348013

163. Deshmukh AP Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing Proc. Natl Acad. Sci. U. S. A. 2021 118 e2102050118 10.1073/pnas.2102050118 33941680 PMC8126782

164. Noman MZ Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges Cells 2019 8 1083 10.3390/cells8091083 31540045 PMC6770817

165. Zheng X Yu C Xu M Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy Front. Oncol. 2021 11 678333 10.3389/fonc.2021.678333 34262865 PMC8273276

166. Capparelli C Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma Nat. Commun. 2022 13 1381 10.1038/s41467-022-28801-y 35296667 PMC8927161

167. Zhou F Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade Adv. Mater. 2019 31 e1805888 10.1002/adma.201805888 30762908

168. Kalluri R Zeisberg M Fibroblasts in cancer Nat. Rev. Cancer 2006 6 392 401 10.1038/nrc1877 16572188

169. Luque M Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer Int. J. Mol. Sci. 2021 22 13297 10.3390/ijms222413297 34948097 PMC8706990

170. Huang TX Guan XY Fu L Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells Am. J. Cancer Res. 2019 9 1889 1904 31598393 PMC6780671

171. Doherty MR Smigiel JM Junk DJ Jackson MW Cancer Stem Cell Plasticity Drives Therapeutic Resistance Cancers (Basel) 2016 8 8 10.3390/cancers8010008 26742077 PMC4728455

172. Yu Y Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling Br. J. Cancer 2014 110 724 732 10.1038/bjc.2013.768 24335925 PMC3915130

173. Luo H Tu G Liu Z Liu M Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression Cancer Lett. 2015 361 155 163 10.1016/j.canlet.2015.02.018 25700776

174. Apicella M Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies Cell Metab. 2018 28 848 865 e846 10.1016/j.cmet.2018.08.006 30174307

175. Gkountakos A Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance Biomedicines 2022 10 277 10.3390/biomedicines10020277 35203491 PMC8869286

176. Straussman R Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012 487 500 504 10.1038/nature11183 22763439 PMC3711467

177. Wilson TR Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 2012 487 505 509 10.1038/nature11249 22763448 PMC3724525

178. Mahaweni NM Bos GMJ Mitsiades CS Tilanus MGJ Wieten L Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions Cancer Immunol. Immunother. 2018 67 861 872 10.1007/s00262-018-2140-1 29500635 PMC5951903

179. Ikeda S Tagawa H Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma Cancer Sci. 2021 112 3995 4004 10.1111/cas.15087 34310776 PMC8486179

180. Barr TA B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells J. Exp. Med 2012 209 1001 1010 10.1084/jem.20111675 22547654 PMC3348102

181. Jung BG Early Secreted Antigenic Target of 6-kDa of Mycobacterium tuberculosis Stimulates IL-6 Production by Macrophages through Activation of STAT3 Sci. Rep. 2017 7 40984 10.1038/srep40984 28106119 PMC5247711

182. Shintani Y IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling J. Thorac. Oncol. 2016 11 1482 1492 10.1016/j.jtho.2016.05.025 27287412

183. Li L Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling Commun. Biol. 2022 5 155 10.1038/s42003-022-03111-7 35197546 PMC8866396

184. Ju X IL-6 regulates extracellular matrix remodeling associated with aortic dilation in a fibrillin-1 hypomorphic mgR/mgR mouse model of severe Marfan syndrome J. Am. Heart Assoc. 2014 3 e000476 10.1161/JAHA.113.000476 24449804 PMC3959679

185. Zoeller JJ Bronson RT Selfors LM Mills GB Brugge JS Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo NPJ Breast Cancer 2017 3 18 10.1038/s41523-017-0020-z 28649658 PMC5460247

186. Fu Y Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer J. Hematol. Oncol. 2020 13 169 10.1186/s13045-020-01009-7 33287873 PMC7720454

187. Despeaux M Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells Leukemia 2011 25 1789 1793 10.1038/leu.2011.145 21647157

188. Namba K Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells Mol. Cancer Res 2019 17 499 507 10.1158/1541-7786.MCR-18-0628 30463991

189. Lee A-F Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells PLoS One 2017 12 e0180383 10.1371/journal.pone.0180383 28683123 PMC5500319

190. Wu DM The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling Cell Death Dis. 2019 10 349 10.1038/s41419-019-1591-4 31024010 PMC6483988

191. Raoof S Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer Oncogene 2019 38 6399 6413 10.1038/s41388-019-0887-2 31324888 PMC6742540

192. Nieszporek A Skrzypek K Adamek G Majka M Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis Acta Biochim. Pol. 2019 66 509 520 31883362 10.18388/abp.2019_2899

193. Chang TH Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor Am. J. Respir. Crit. Care Med 2011 183 1071 1079 10.1164/rccm.201009-1440OC 21037017

194. Hao Y Baker D Ten Dijke P TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis Int. J. Mol. Sci. 2019 20 2767 10.3390/ijms20112767 31195692 PMC6600375

195. Hua W Ten Dijke P Kostidis S Giera M Hornsveld M TGFbeta-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer Cell Mol. Life Sci. 2020 77 2103 2123 10.1007/s00018-019-03398-6 31822964 PMC7256023

196. Santamaria PG Moreno-Bueno G Cano A Contribution of Epithelial Plasticity to Therapy Resistance J. Clin. Med 2019 8 676 10.3390/jcm8050676 31091749 PMC6571660

197. Colak S Ten Dijke P Targeting TGF-β Signaling in Cancer Trends Cancer 2017 3 56 71 10.1016/j.trecan.2016.11.008 28718426

198. Xu W Yang Z Lu N A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition Cell Adh Migr. 2015 9 317 324 10.1080/19336918.2015.1016686 26241004 PMC4594353

199. Lee MK TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA EMBO J. 2007 26 3957 3967 10.1038/sj.emboj.7601818 17673906 PMC1994119

200. Katsuno Y Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition Sci. Signal 2019 12 eaau8544 10.1126/scisignal.aau8544 30808819 PMC6746178

201. Pan G Liu Y Shang L Zhou F Yang S EMT-associated microRNAs and their roles in cancer stemness and drug resistance Cancer Commun. (Lond.) 2021 41 199 217 10.1002/cac2.12138 33506604 PMC7968884

202. Zhang J Ma L MicroRNA control of epithelial-mesenchymal transition and metastasis Cancer Metastasis Rev. 2012 31 653 662 10.1007/s10555-012-9368-6 22684369 PMC3686549

203. Li J Yu H Xi M Ma D Lu X The SNAI1 3’UTR functions as a sponge for multiple migration-/invasion-related microRNAs Tumour Biol. 2015 36 1067 1072 10.1007/s13277-014-2733-z 25326810

204. Xiao B Shi X Bai J miR-30a regulates the proliferation and invasion of breast cancer cells by targeting Snail Oncol. Lett. 2019 17 406 413 30655781 10.3892/ol.2018.9552 PMC6313185

205. Liu YN MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms Oncogene 2013 32 296 306 10.1038/onc.2012.58 22370643 PMC7580497

206. Dou R EMT-cancer cells-derived exosomal miR-27b-3p promotes circulating tumour cells-mediated metastasis by modulating vascular permeability in colorectal cancer Clin. Transl. Med 2021 11 e595 10.1002/ctm2.595 34936736 PMC8694332

207. Lu N miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma Oncol. Rep. 2021 45 706 716 10.3892/or.2020.7880 33416185 PMC7757091

208. Li Y Long X Wang J Peng J Shen K miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways J. Orthop. Surg. Res. 2021 16 71 10.1186/s13018-020-02164-w 33472642 PMC7816476

209. Wang D MiRNA-155-5p inhibits epithelium-to-mesenchymal transition (EMT) by targeting GSK-3β during radiation-induced pulmonary fibrosis Arch. Biochem. Biophys. 2021 697 108699 10.1016/j.abb.2020.108699 33259794

210. Dagogo-Jack I Shaw AT Tumour heterogeneity and resistance to cancer therapies Nat. Rev. Clin. Oncol. 2018 15 81 94 10.1038/nrclinonc.2017.166 29115304

211. Fanelli GN Naccarato AG Scatena C Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization Front Oncol. 2020 10 569 10.3389/fonc.2020.00569 32391266 PMC7188928

212. Morel AP Generation of breast cancer stem cells through epithelial-mesenchymal transition PLoS One 2008 3 e2888 10.1371/journal.pone.0002888 18682804 PMC2492808

213. Nimmakayala RK Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma Oncogene 2021 40 215 231 10.1038/s41388-020-01518-2 33110235 PMC10041665

214. Lei X Cancer stem cells in colorectal cancer and the association with chemotherapy resistance Med. Oncol. 2021 38 43 10.1007/s12032-021-01488-9 33738588

215. Lam K-H Ma S Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications Hepatology 2022 21 1 15 10.1002/hep.32629 35727189

216. Quintana E Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized Cancer Cell 2010 18 510 523 10.1016/j.ccr.2010.10.012 21075313 PMC3031091

217. Boiko AD Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 Nature 2010 466 133 137 10.1038/nature09161 20596026 PMC2898751

218. Charles N Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells Cell Stem Cell 2010 6 141 152 10.1016/j.stem.2010.01.001 20144787 PMC3818090

219. Nakano M Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer Oncogene 2019 38 780 793 10.1038/s41388-018-0480-0 30181548

220. de Sousa e Melo F A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer Nature 2017 543 676 680 10.1038/nature21713 28358093

221. Oxnard GR Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol. 2016 34 3375 3382 10.1200/JCO.2016.66.7162 27354477 PMC5035123

222. Chabon JJ Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients Nat. Commun. 2016 7 11815 10.1038/ncomms11815 27283993 PMC4906406

223. Suda K Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer Lung Cancer 2016 91 36 40 10.1016/j.lungcan.2015.11.016 26711932

224. Le Magnen C Shen MM Abate-Shen C Lineage Plasticity in Cancer Progression and Treatment Annu Rev. Cancer Biol. 2018 2 271 289 10.1146/annurev-cancerbio-030617-050224 29756093 PMC5942183

225. Easwaran H A DNA hypermethylation module for the stem/progenitor cell signature of cancer Genome Res 2012 22 837 849 10.1101/gr.131169.111 22391556 PMC3337430

226. Xiao Y Yu D Tumor microenvironment as a therapeutic target in cancer Pharm. Ther. 2021 221 107753 10.1016/j.pharmthera.2020.107753 PMC8084948 33259885

227. Anderson NM Simon MC The tumor microenvironment Curr. Biol. 2020 30 R921 r925 10.1016/j.cub.2020.06.081 32810447 PMC8194051

228. Hanahan D Coussens LM Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 2012 21 309 322 10.1016/j.ccr.2012.02.022 22439926

229. Baghban R Tumor microenvironment complexity and therapeutic implications at a glance Cell Commun. Signal. 2020 18 59 10.1186/s12964-020-0530-4 32264958 PMC7140346

230. Lequeux A Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints Cancer Lett. 2019 458 13 20 10.1016/j.canlet.2019.05.021 31136782

231. Paolicchi E Targeting hypoxic response for cancer therapy Oncotarget 2016 7 13464 13478 10.18632/oncotarget.7229 26859576 PMC4924654

232. Bae HJ Liu S Jin P Stroncek D Mesenchymal stromal cell plasticity and the tumor microenvironment Emerg. Top. Life Sci. 2017 1 487 492 10.1042/ETLS20170141 33525796

233. Wang X Zhang H Chen X Drug resistance and combating drug resistance in cancer Cancer Drug Resist 2019 2 141 160 34322663 10.20517/cdr.2019.10 PMC8315569

234. Reynolds TY Rockwell S Glazer PM Genetic instability induced by the tumor microenvironment Cancer Res 1996 56 5754 5757 8971187

235. Zhang A Miao K Sun H Deng CX Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance Int. J. Biol. Sci. 2022 18 3019 3033 10.7150/ijbs.72534 35541919 PMC9066118

236. Rambow F Toward minimal residual disease-directed therapy in melanoma Cell 2018 174 843 855. e819 10.1016/j.cell.2018.06.025 30017245

237. Ramirez M Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells Nat. commun. 2016 7 1 8 10.1038/ncomms10690 PMC4762880 26891683

238. Tan C-S Gilligan D Pacey S Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer Lancet Oncol. 2015 16 e447 e459 10.1016/S1470-2045(15)00246-6 26370354

239. Winder M Virós A Mechanisms of drug resistance in melanoma Handb. Exp. Pharm. 2018 249 91 108 10.1007/164_2017_17 28275910

240. Sharma SV A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 2010 141 69 80 10.1016/j.cell.2010.02.027 20371346 PMC2851638

241. Ravindran Menon D A stress-induced early innate response causes multidrug tolerance in melanoma Oncogene 2015 34 4448 4459 10.1038/onc.2014.372 25417704 PMC4442085

242. Liau BB Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance cell stem cell 2017 20 233 246. e237 10.1016/j.stem.2016.11.003 27989769 PMC5291795

243. Kruidenier L A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response Nature 2012 488 404 408 10.1038/nature11262 22842901 PMC4691848

244. Heinemann B Inhibition of demethylases by GSK-J1/J4 Nature 2014 514 E1 E2 10.1038/nature13688 25279926

245. Johansson C Structural analysis of human KDM5B guides histone demethylase inhibitor development Nat. Chem. Biol. 2016 12 539 545 10.1038/nchembio.2087 27214403

246. Yang GJ Selective inhibition of lysine‐specific demethylase 5A (KDM5A) using a rhodium (III) complex for triple‐negative breast cancer therapy Angew. Chem. Int Ed. Engl. 2018 57 13091 13095 10.1002/anie.201807305 29968419

247. Liu J Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 Proc. Natl Acad. Sci. U. S. A. 2013 110 20224 20229 10.1073/pnas.1314239110 24277854 PMC3864356

248. Liang X Lin A Wang Q Zhang J Luo P Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC Biomed. Pharmacother. 2022 149 112909 10.1016/j.biopha.2022.112909 36068773

249. Marcoux N EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes J. Clin. Oncol. 2019 37 278 10.1200/JCO.18.01585 30550363 PMC7001776

250. Hangauer MJ Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition Nature 2017 551 247 250 10.1038/nature24297 29088702 PMC5933935

251. Friedmann Angeli JP Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice Nat. Cell Biol. 2014 16 1180 1191 10.1038/ncb3064 25402683 PMC4894846

252. Yoo S-E Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain Free Radic. Biol. Med. 2012 52 1820 1827 10.1016/j.freeradbiomed.2012.02.043 22401858 PMC3341497

253. Eaton JK Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles Nat. Chem. Biol. 2020 16 497 506 10.1038/s41589-020-0501-5 32231343 PMC7251976

254. Santamaria PG Moreno-Bueno G Portillo F Cano A EMT: Present and future in clinical oncology Mol. Oncol. 2017 11 718 738 10.1002/1878-0261.12091 28590039 PMC5496494

255. Voon DC Huang RY Jackson RA Thiery JP The EMT spectrum and therapeutic opportunities Mol. Oncol. 2017 11 878 891 10.1002/1878-0261.12082 28544151 PMC5496500

256. Baram T Rubinstein-Achiasaf L Ben-Yaakov H Ben-Baruch A Inflammation-driven breast tumor cell plasticity: stemness/EMT, therapy resistance and dormancy Front. Oncol. 2021 10 614468 10.3389/fonc.2020.614468 33585241 PMC7873936

257. Hasan T Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma Cell Death Dis. 2019 10 1 17 10.1038/s41419-019-1387-6 PMC6441047 30926789

258. Fousek K Horn LA Palena C Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression Pharmacol. Ther. 2021 219 107692 10.1016/j.pharmthera.2020.107692 32980444 PMC8344087

259. Xiao P Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells Oncoimmunology 2018 7 e1440166 10.1080/2162402X.2018.1440166 29900041 PMC5993481

260. Kahraman DC Kahraman T Cetin-Atalay R Targeting PI3K/Akt/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment Mol. Cancer Ther. 2019 18 2146 2157 10.1158/1535-7163.MCT-19-0004 31439713

261. Dominguez C McCampbell KK David JM Palena C Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer JCI insight 2017 2 e94296 10.1172/jci.insight.94296 29093275 PMC5752275

262. Fernando RI IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib Oncotarget 2016 7 42031 10.18632/oncotarget.9662 27248176 PMC5173114

263. Devapatla B Sharma A Woo S CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer PLoS One 2015 10 e0139237 10.1371/journal.pone.0139237 26414070 PMC4587670

264. Xu J Lamouille S Derynck R TGF-β-induced epithelial to mesenchymal transition Cell Res 2009 19 156 172 10.1038/cr.2009.5 19153598 PMC4720263

265. Grauel AL TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts Nat. commun. 2020 11 1 17 10.1038/s41467-020-19920-5 33298926 PMC7725805

266. Massagué J TGFβ signalling in context Nat. Rev. Mol. 2012 13 616 630 10.1038/nrm3434 PMC4027049 22992590

267. Akhurst RJ Hata A Targeting the TGFβ signalling pathway in disease Nat. Rev. Drug Disco. 2012 11 790 811 10.1038/nrd3810 PMC3520610 23000686

268. de Gramont A Faivre S Raymond E Novel TGF-β inhibitors ready for prime time in onco-immunology Oncoimmunology 2017 6 e1257453 10.1080/2162402X.2016.1257453 28197376 PMC5283641

269. Pattabiraman DR Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability Science 2016 351 aad3680 10.1126/science.aad3680 26941323 PMC5131720

270. Yingling JM Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor Oncotarget 2018 9 6659 10.18632/oncotarget.23795 29467918 PMC5805504

271. Melisi D Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer Br. J. Cancer 2018 119 1208 1214 10.1038/s41416-018-0246-z 30318515 PMC6251034

272. Horn LA Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication J. Clin. Investig. 2022 132 e155148 10.1172/JCI155148 35230974 PMC9012291

273. Xing Y Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer Acta Pharmacol. Sin. 2022 43 2410 2418 10.1038/s41401-021-00840-z 35082394 PMC9433380

274. Gan L Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential Biomark. Res. 2018 6 1 10 10.1186/s40364-018-0122-2 29556394 PMC5845366

275. Gallardo A EZH2 endorses cell plasticity to carcinoma cells facilitating mesenchymal to epithelial transition and tumour colonization Oncogene 2022 41 3611 3624 10.1038/s41388-022-02375-x 35680984

276. Dardenne E N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer Cancer Cell 2016 30 563 577 10.1016/j.ccell.2016.09.005 27728805 PMC5540451

277. Knutson SK Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma Mol. Cancer Ther. 2014 13 842 854 10.1158/1535-7163.MCT-13-0773 24563539

278. Vaswani RG Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl) piperidin-4-yl) ethyl)-1 H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas J. Med. Chem. 2016 59 9928 9941 10.1021/acs.jmedchem.6b01315 27739677 PMC5451150

279. Gagliardi M Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis Cell Death Dis. 2019 10 902 10.1038/s41419-019-2143-7 31780644 PMC6883066

280. Igarashi K Nishizawa H Saiki Y Matsumoto M The transcription factor BACH1 at the crossroads of cancer biology: From epithelial-mesenchymal transition to ferroptosis J. Biol. Chem. 2021 297 101032 10.1016/j.jbc.2021.101032 34339740 PMC8387770

281. Xie J Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma Signal Transduct. Target Ther. 2021 6 333 10.1038/s41392-021-00702-4 34482361 PMC8418605

282. Liu Y Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis J. Hepatol. 2022 76 652 664 10.1016/j.jhep.2021.11.010 34793870 PMC8858854

283. Pei J Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery J. Med. Chem. 2021 64 3493 3507 10.1021/acs.jmedchem.0c01689 33764774

284. Sievers QL Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN Science 2018 362 eaat0572 10.1126/science.aat0572 30385546 PMC6326779

285. Kong F-E Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate Sci. Transl. Med. 2021 13 eabb6282 10.1126/scitranslmed.abb6282 33536280

286. Huang F Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses J. Clin. Investig. 2021 131 e140752 10.1172/JCI140752 33690225 PMC8262472

287. Chae YK Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC) Sci. Rep. 2018 8 2918 10.1038/s41598-018-21061-1 29440769 PMC5811447

288. Lou Y Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma Clin. Cancer Res 2016 22 3630 3642 10.1158/1078-0432.CCR-15-1434 26851185 PMC4947453

289. Wu T PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers Front. Immunol. 2021 12 693881 10.3389/fimmu.2021.693881 34552581 PMC8450501

290. Guo Y Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells Sci. Adv. 2021 7 eabd7455 10.1126/sciadv.abd7455 34020945 PMC8139582

291. Zhao K TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism Cancer Immunol. Immunother. 2023 72 193 209 10.1007/s00262-022-03227-z 35794399 PMC9813151

292. Mahmoudian RA Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC J. Mol. Histol. 2021 52 597 609 10.1007/s10735-021-09971-3 33884540

293. Chen X eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma J. Immunother. Cancer 2022 10 e004026 10.1136/jitc-2021-004026 35347072 PMC8961175

294. Wu Y Effect of ISM1 on the Immune Microenvironment and Epithelial-Mesenchymal Transition in Colorectal Cancer Front Cell Dev. Biol. 2021 9 681240 10.3389/fcell.2021.681240 34350177 PMC8326811

295. Dongre A Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas Cancer Res 2017 77 3982 3989 10.1158/0008-5472.CAN-16-3292 28428275 PMC5541771

296. Wu Q MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma Cancer Commun. (Lond.) 2021 41 1354 1372 10.1002/cac2.12203 34347390 PMC8696229

297. Kim S PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung Hum. Pathol. 2016 58 7 14 10.1016/j.humpath.2016.07.007 27473266

298. Cui M Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers Front Genet 2021 12 688207 10.3389/fgene.2021.688207 35087563 PMC8787320

299. Cao L Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer Front Genet 2022 13 801484 10.3389/fgene.2022.801484 35281839 PMC8907673

300. Song J Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction Mol. Med. 2022 28 47 10.1186/s10020-022-00475-8 35508972 PMC9066895

301. Yang CY Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Eur. J. Cancer 2020 124 110 122 10.1016/j.ejca.2019.10.019 31760310

302. Isomoto K Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer Clin. Cancer Res 2020 26 2037 2046 10.1158/1078-0432.CCR-19-2027 31937613

303. Haratani K Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment Ann. Oncol. 2017 28 1532 1539 10.1093/annonc/mdx183 28407039

304. Jia Y EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies Int. J. Cancer 2019 145 1432 1444 10.1002/ijc.32191 30784054

305. Tian T Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation Front. Oncol. 2021 11 739090 10.3389/fonc.2021.739090 34888234 PMC8648573

306. Chen Y Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer Future Oncol. 2022 18 1757 1775 10.2217/fon-2021-0862 35232247

307. Jiang T Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial Signal Transduct. Target Ther. 2021 6 355 10.1038/s41392-021-00751-9 34650034 PMC8517012

308. Liu S Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC Front. Oncol. 2021 11 639947 10.3389/fonc.2021.639947 33777802 PMC7991800

309. Greten TF Lai CW Li G Staveley-O’Carroll KF Targeted and Immune-Based Therapies for Hepatocellular Carcinoma Gastroenterology 2019 156 510 524 10.1053/j.gastro.2018.09.051 30287171 PMC6340758

310. Shemesh CS Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region Liver Cancer 2021 10 485 499 10.1159/000515817 34721510 PMC8527900

311. Qin S Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Liver Cancer 2021 10 296 308 10.1159/000513486 34414118 PMC8339481

312. Rizzo A Ricci AD Gadaleta-Caldarola G Brandi G First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges Expert Rev. Gastroenterol. Hepatol. 2021 15 1245 1251 10.1080/17474124.2021.1973431 34431725

313. Cheng AL Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma J. Hepatol. 2022 76 862 873 10.1016/j.jhep.2021.11.030 34902530

314. Tang Z ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer Clin. Cancer Res 2021 27 4898 4909 10.1158/1078-0432.CCR-21-1010 34168048 PMC8456453

315. Siewe N Friedman A Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model PLoS One 2022 17 e0262453 10.1371/journal.pone.0262453 35015785 PMC8752026

316. Guan X Androgen receptor activity in T cells limits checkpoint blockade efficacy Nature 2022 606 791 796 10.1038/s41586-022-04522-6 35322234 PMC10294141

317. Wang Y Ma X Wei Y Ma D Gong P Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma Med. (Baltim.) 2018 97 e9602 10.1097/MD.0000000000009602 PMC5794360 29369176

318. Leonetti A Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer Drug Resist Updat 2019 46 100644 10.1016/j.drup.2019.100644 31585395

319. Borghaei H Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials Cancer 2020 126 4867 4877 10.1002/cncr.33142 32914866 PMC7692929

320. Zhang J MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies J. Thorac. Oncol. 2019 14 s292 10.1016/j.jtho.2019.08.587

321. Reck M Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Lancet Respir. Med 2019 7 387 401 10.1016/S2213-2600(19)30084-0 30922878

322. Janjigian YY First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 2021 398 27 40 10.1016/S0140-6736(21)00797-2 34102137 PMC8436782

323. Janjigian YY The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer Nature 2021 600 727 730 10.1038/s41586-021-04161-3 34912120 PMC8959470

324. Miles D Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Ann. Oncol. 2021 32 994 1004 10.1016/j.annonc.2021.05.801 34219000

325. Schmid P Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer N. Engl. J. Med. 2018 379 2108 2121 10.1056/NEJMoa1809615 30345906

326. Zhang Y Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer Cancer Cell 2021 39 1578 1593 e1578 10.1016/j.ccell.2021.09.010 34653365

327. Lu Q Bioengineered Platelets Combining Chemotherapy and Immunotherapy for Postsurgical Melanoma Treatment: Internal Core-Loaded Doxorubicin and External Surface-Anchored Anti-PD-L1 Antibody Backpacks Nano Lett. 2022 22 3141 3150 10.1021/acs.nanolett.2c00907 35318846

328. Ahn MJ Sun JM Lee SH Ahn JS Park K EGFR TKI combination with immunotherapy in non-small cell lung cancer Expert Opin. Drug Saf. 2017 16 465 469 10.1080/14740338.2017.1300656 28271729

329. Yang JC Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report J. Thorac. Oncol. 2019 14 933 939 10.1016/j.jtho.2019.02.001 30763730

330. Oxnard GR TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer Ann. Oncol. 2020 31 507 516 10.1016/j.annonc.2020.01.013 32139298

331. Oshima Y Tanimoto T Yuji K Tojo A EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer JAMA Oncol. 2018 4 1112 1115 10.1001/jamaoncol.2017.4526 29327061 PMC5885195

332. Jia Y Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice Lung Cancer 2019 137 85 93 10.1016/j.lungcan.2019.09.016 31563735

333. Schoenfeld AJ Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib Ann. Oncol. 2019 30 839 844 10.1093/annonc/mdz077 30847464 PMC7360149

334. Ribas A Hodi FS Callahan M Konto C Wolchok J Hepatotoxicity with combination of vemurafenib and ipilimumab N. Engl. J. Med. 2013 368 1365 1366 10.1056/NEJMc1302338 23550685

335. Yu Y Multi-target combinatory strategy to overcome tumor immune escape Front. Med. 2022 16 208 215 10.1007/s11684-022-0922-5 35377102

336. Wolchok JD Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma N. Engl. J. Med. 2017 377 1345 1356 10.1056/NEJMoa1709684 28889792 PMC5706778

337. Kariolis MS Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies J. Clin. Invest 2017 127 183 198 10.1172/JCI85610 27893463 PMC5199716

338. Leconet W Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis Clin. Cancer Res 2017 23 2806 2816 10.1158/1078-0432.CCR-16-1316 27923843

339. Ghiso E YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC Neoplasia 2017 19 1012 1021 10.1016/j.neo.2017.10.003 29136529 PMC5683041

340. Yu M YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD Cell Death Dis. 2018 9 464 10.1038/s41419-018-0515-z 29700328 PMC5920099

341. Nyakas M AXL inhibition improves BRAF-targeted treatment in melanoma Sci. Rep. 2022 12 5076 10.1038/s41598-022-09078-z 35332208 PMC8948193

342. Scherschinski L Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma Int. J. Mol. Sci. 2022 23 982 10.3390/ijms23020982 35055167 PMC8781963

343. Shen Y Chen X He J Liao D Zu X Axl inhibitors as novel cancer therapeutic agents Life Sci. 2018 198 99 111 10.1016/j.lfs.2018.02.033 29496493

344. Myers SH Brunton VG Unciti-Broceta A AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective J. Med. Chem. 2016 59 3593 3608 10.1021/acs.jmedchem.5b01273 26555154

345. Wang J Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness Cancer Lett. 2018 415 73 85 10.1016/j.canlet.2017.11.037 29199005

346. Wang C Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis Int. J. Biochem. Cell Biol. 2012 44 2308 2320 10.1016/j.biocel.2012.09.012 23010347

347. Praharaj PP Patra S Panigrahi DP Patra SK Bhutia SK Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy Biochim Biophys. Acta Rev. Cancer 2021 1875 188500 10.1016/j.bbcan.2020.188500 33385484

348. Shahbaz S CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β PLoS Biol. 2018 16 e2006649 10.1371/journal.pbio.2006649 30550561 PMC6310287

349. Yingling JM Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-beta receptor type I inhibitor Oncotarget 2018 9 6659 6677 10.18632/oncotarget.23795 29467918 PMC5805504

350. Song B Targeting FOXA1-mediated repression of TGF-beta signaling suppresses castration-resistant prostate cancer progression J. Clin. Invest 2019 129 569 582 10.1172/JCI122367 30511964 PMC6355239

351. Kelley RK A Phase 2 Study of Galunisertib (TGF-beta1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Clin. Transl. Gastroenterol. 2019 10 e00056 10.14309/ctg.0000000000000056 31295152 PMC6708671

352. Harding JJ Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma Cancer Med 2021 10 3059 3067 10.1002/cam4.3880 33811482 PMC8085979

353. Wick A Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Invest. N. Drugs 2020 38 1570 1579 10.1007/s10637-020-00910-9 PMC7497674 32140889

354. Melisi D Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer J. Immunother. Cancer 2021 9 e002068 10.1136/jitc-2020-002068 33688022 PMC7944986

355. Tauriello DVF TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis Nature 2018 554 538 543 10.1038/nature25492 29443964

356. Lan Y Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta Sci. Transl. Med. 2018 10 eaan5488 10.1126/scitranslmed.aan5488 29343622

357. Knudson KM M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine Oncoimmunology 2018 7 e1426519 10.1080/2162402X.2018.1426519 29721396 PMC5927523

358. Ravi R Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy Nat. Commun. 2018 9 741 10.1038/s41467-017-02696-6 29467463 PMC5821872

359. Strauss J Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with human papillomavirus-associated malignancies J. Immunother. Cancer 2020 8 e001395 10.1136/jitc-2020-001395 33323462 PMC7745517

360. Tan B Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort Target. Oncol. 2021 16 435 446 10.1007/s11523-021-00809-2 34009501 PMC8266790

361. Yoo C Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer J. Immunother. Cancer 2020 8 e000564 10.1136/jitc-2020-000564 32461347 PMC7254161

362. Ma F Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer Cancer Res 2022 82 1518 1533 10.1158/0008-5472.CAN-21-1807 35131873 PMC9018564

363. Moore KN A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer Gynecol. Oncol. 2019 154 294 301 10.1016/j.ygyno.2019.04.001 31174889 PMC7397408

364. Dotan E Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer Clin. Cancer Res 2020 26 5348 5357 10.1158/1078-0432.CCR-20-0489 32694153 PMC7572624

365. Kaur A WNT inhibition creates a BRCA-like state in Wnt-addicted cancer EMBO Mol. Med. 2021 13 e13349 10.15252/emmm.202013349 33660437 PMC8033517

366. Le PN Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions Mol. Carcinog. 2019 58 398 410 10.1002/mc.22937 30378175 PMC6460915

367. Sun L Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy JCI Insight 2019 4 e126853 10.1172/jci.insight.126853 30944253 PMC6483637

368. Greene S Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models Clin. Cancer Res 2020 26 1420 1431 10.1158/1078-0432.CCR-19-2625 31848188 PMC7073293

369. Kim MJ Reduced HIF-1α Stability Induced by 6-Gingerol Inhibits Lung Cancer Growth through the Induction of Cell Death Molecules 2022 27 2106 10.3390/molecules27072106 35408505 PMC9000891

370. Tirpe AA Gulei D Ciortea SM Crivii C Berindan-Neagoe I Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes Int. J. Mol. Sci. 2019 20 6140 10.3390/ijms20246140 31817513 PMC6941045

371. Qin Y Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway EBioMedicine 2018 38 25 36 10.1016/j.ebiom.2018.10.069 30396856 PMC6306459

372. Minoura K Abe K Nam H Nishikawa H Shimamura T A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data Cell Rep. Methods 2021 1 100071 10.1016/j.crmeth.2021.100071 35474667 PMC9017195

373. Longo SK Guo MG Ji AL Khavari PA Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics Nat. Rev. Genet. 2021 22 627 644 10.1038/s41576-021-00370-8 34145435 PMC9888017

374. Song WM Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis Nat. Commun. 2021 12 1214 10.1038/s41467-021-21457-0 33619278 PMC7900178